Schaaf-Yang Syndrome

Mendelian MONDO:0014243 Pathograph 38 Show in embeddings browser autosomal dominant syndromic intellectual disability autism spectrum disorder

Schaaf-Yang syndrome (SYS; OMIM 615547) is a rare autosomal dominant, maternally imprinted neurodevelopmental disorder caused by truncating pathogenic variants in the paternally expressed allele of MAGEL2, one of the protein-coding genes within the Prader-Willi critical region at 15q11-q13. Because MAGEL2 is maternally imprinted, only the paternally derived allele is transcribed, so a truncating variant on that allele (whether paternally inherited or a de novo variant on the paternal chromosome) leaves the individual without functional MAGEL2. SYS shares many features with the genetically related Prader-Willi syndrome — neonatal hypotonia, feeding difficulties that can transition to hyperphagia and obesity, developmental delay, and hypogonadism — but is clinically distinguished by a high frequency of distal joint contractures (ranging to arthrogryposis multiplex congenita and fetal akinesia at the severe end) and a strikingly elevated rate of autism spectrum disorder and more severe intellectual disability. MAGEL2 encodes a single-exon MAGE-family protein that scaffolds the MAGE-L2-TRIM27 ubiquitin ligase governing WASH-dependent, retromer-mediated endosomal protein recycling, and it modulates hypothalamic oxytocin and neuroendocrine systems. The prevailing model combines loss of MAGEL2 function with a possible neomorphic or toxic effect of the stable, nuclear-mislocalized truncated protein, since whole-gene deletions of paternal MAGEL2 produce little or no phenotype.

Ask OpenScientist

Ask a research question about Schaaf-Yang Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
25
Phenotypes
2
Hypotheses
38
Pathograph
1
Genes
5
Medical Actions
11
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
SYS is inherited in an autosomal dominant, maternally imprinted manner: a heterozygous pathogenic variant on the paternally derived MAGEL2 allele causes disease, whereas the same variant on the maternally derived allele does not, because the maternal MAGEL2 allele is normally silenced. Approximately half of affected individuals inherited the variant from a clinically unaffected father, and the remainder are de novo.
Autosomal dominant inheritance Penetrance: UNKNOWN Expressivity: VARIABLE
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"Schaaf-Yang syndrome is inherited in an autosomal dominant, maternally imprinted manner (i.e., a heterozygous pathogenic variant on the paternally derived MAGEL2 allele results in disease; a pathogenic variant on the maternally derived MAGEL2 allele does not result in disease because normally..."
GeneReviews states the autosomal dominant, maternally imprinted mode of inheritance.
PMID:33570896 SUPPORT Human Clinical
"Approximately 50% of individuals diagnosed with SYS inherited a MAGEL2 pathogenic variant from a clinically unaffected father and the remainder are de novo."
GeneReviews quantifies the inherited-versus-de-novo split, reflecting the maternal imprinting of MAGEL2.
◈

Mechanistic Hypotheses

2
MAGEL2 Loss-of-Function Branch
magel2_loss_of_function CANONICAL
Evidence balance 1 support
Because MAGEL2 is expressed only from the paternal allele, a truncating variant on that allele leaves the individual with no functional MAGEL2 protein (functional hemizygosity). Loss of MAGEL2's role in retromer/WASH-dependent endosomal recycling and hypothalamic neuroendocrine regulation is proposed to underlie many SYS (and shared PWS) phenotypes.
Pathograph links
MAGEL2 Truncating Variant on the Expressed Paternal Allele -> Loss of Functional MAGEL2 Protein DIRECT
Loss of Functional MAGEL2 Protein -> Impaired MAGE-L2-TRIM27 Endosomal Protein Recycling DIRECT
Loss of Functional MAGEL2 Protein -> Hypothalamic Oxytocin Deficiency DIRECT
Loss of Functional MAGEL2 Protein -> Progressive Hypothalamic Leptin Resistance INDIRECT UNKNOWN INTERMEDIATES
Loss of Functional MAGEL2 Protein -> Reduced Fetal Movement and Distal Contracture Formation INDIRECT UNKNOWN INTERMEDIATES
Hypothalamic Oxytocin Deficiency -> Neonatal Suckling and Feeding Failure DIRECT
Show evidence (1 reference)
PMID:24076603 SUPPORT Human Clinical
"Given the functional hemizygosity for this gene, a truncating mutation on the paternal allele leaves affected individuals without functional, expressed MAGEL2, making it potentially pathogenic."
The discovery paper frames SYS as loss of functional MAGEL2 owing to paternal-allele functional hemizygosity.
Neomorphic Truncated-Protein Branch
truncated_protein_neomorphic EMERGING
Evidence balance 2 support
Loss of function alone does not fully explain SYS, because whole-gene deletions of paternal MAGEL2 produce little or no phenotype whereas truncating variants cause disease. Patient-derived and cell-based studies show that the truncated MAGEL2 protein is stable and mislocalizes to the nucleus, suggesting an additional neomorphic/toxic gain-of-function contribution beyond simple haploinsufficiency.
Pathograph links
MAGEL2 Truncating Variant on the Expressed Paternal Allele -> Stable Nuclear-Mislocalized Truncated MAGEL2 DIRECT
Show evidence (2 references)
PMID:36243518 SUPPORT In Vitro
"The truncated form of MAGEL2 displayed a stability similar to the WT but it was significantly switched to the nucleus, compared with a mainly cytoplasmic distribution of the WT MAGEL2."
Nuclear mislocalization of a stable truncated protein supports a neomorphic mechanism distinct from a simple null.
PMID:27195816 SUPPORT Human Clinical
"the pathogenicity of truncating mutations of the paternal allele of MAGEL2 has been questioned, due to the small number of cases reported, but also because whole-gene deletions of the paternal copy of MAGEL2 appear to have no phenotype or very mild phenotypes."
The deletion-versus-truncation discrepancy is the clinical observation motivating a non-null (neomorphic) contribution.
⚙

Pathophysiology

8
MAGEL2 Truncating Variant on the Expressed Paternal Allele
The initiating lesion is a truncating (nonsense or frameshift) pathogenic variant in MAGEL2 on the paternally expressed allele. MAGEL2 is a single-exon gene within the maternally imprinted Prader-Willi region at 15q11-q13, so only the paternal allele is transcribed; a truncating variant on that allele removes the C-terminal MAGE homology domain from the expressed protein.
MAGEL2 Loss-of-Function Branch Neomorphic Truncated-Protein Branch
MAGEL2 hgnc:6814 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MAGEL2 (hgnc:6814). hgnc:6814 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Loss of Functional MAGEL2 Protein MAGEL2 Loss-of-Function Branch
Stable Nuclear-Mislocalized Truncated MAGEL2 Neomorphic Truncated-Protein Branch
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"The diagnosis of Schaaf-Yang syndrome is established in a proband by identification of a heterozygous pathogenic variant in the paternally derived MAGEL2 allele by molecular genetic testing."
GeneReviews establishes that a variant on the paternally derived MAGEL2 allele is the molecular cause.
Loss of Functional MAGEL2 Protein
With no functional MAGEL2 expressed, the MAGE-L2-TRIM27 ubiquitin-ligase scaffold that normally supports endosomal protein recycling and hypothalamic neuroendocrine function is lost. This loss-of-function is proposed to underlie phenotypes shared with Prader-Willi syndrome.
MAGEL2 Loss-of-Function Branch
Downstream
Impaired MAGE-L2-TRIM27 Endosomal Protein Recycling MAGEL2 Loss-of-Function Branch
Hypothalamic Oxytocin Deficiency MAGEL2 Loss-of-Function Branch
Progressive Hypothalamic Leptin Resistance MAGEL2 Loss-of-Function Branch
Neonatal Hypotonia
Developmental Delay and Intellectual Disability
Autism Spectrum Disorder
Neonatal Respiratory Distress
Hypogonadism
Short Stature
Seizures
Scoliosis
Decreased Bone Mineral Density
Sleep Apnea
Reduced Fetal Movement and Distal Contracture Formation MAGEL2 Loss-of-Function Branch
Facial Dysmorphism
Eye Abnormalities
Cryptorchidism
Hypothyroidism
Gastroesophageal Reflux
Constipation
Small Hands
Small Feet
Impulsive and Compulsive Behavioral Profile
Habitual Skin Picking
Show evidence (1 reference)
PMID:38950199 SUPPORT Human Clinical
"while MAGEL2 loss-of-function seems to underlie several SYS and PWS phenotypes, additional pathomechanisms probably contribute to the distinct and severe phenotype observed in SYS"
A current review attributes several phenotypes to MAGEL2 loss of function while noting additional mechanisms in SYS.
Stable Nuclear-Mislocalized Truncated MAGEL2
Distinct from a simple null, the truncated MAGEL2 protein produced by SYS variants is stable and shifts to a predominantly nuclear distribution (versus the cytoplasmic wild-type). This supports a neomorphic/toxic gain-of-function contribution that may explain why truncating variants cause disease while whole-gene deletions largely do not, and is associated with altered fibroblast transcriptomic and metabolomic profiles.
Show evidence (1 reference)
PMID:36243518 SUPPORT In Vitro
"We also identified 132 differentially expressed genes, including non-coding RNAs (ncRNAs) such as HOTAIR, and many of them related to developmental processes and mitotic mechanisms."
Patient fibroblasts carrying truncated MAGEL2 show a distinct transcriptomic signature consistent with an active molecular consequence.
Impaired MAGE-L2-TRIM27 Endosomal Protein Recycling
MAGEL2 forms the substrate-recognition module of the MAGE-L2-TRIM27 RING ubiquitin ligase, which localizes to endosomes via the retromer and K63-ubiquitinates WASH to nucleate endosomal F-actin required for retromer-mediated cargo recycling. Loss of this activity impairs retrograde endosome-to-Golgi transport and recycling of surface receptors, disturbing neuronal and neuroendocrine cell function.
retrograde endosome-to-Golgi transport GO:0042147 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves retrograde endosome-to-Golgi transport, annotated with retrograde transport, endosome to Golgi (GO:0042147). GO:0042147 is a biological process from the Gene Ontology. K63-linked ubiquitination of WASH by MAGE-L2-TRIM27 GO:0070534 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased K63-linked ubiquitination of WASH by MAGE-L2-TRIM27, annotated with protein K63-linked ubiquitination (GO:0070534). GO:0070534 is a biological process from the Gene Ontology. ↓ DECREASED
retromer cargo-selective complex GO:0030906 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves retromer cargo-selective complex, annotated with retromer, cargo-selective complex (GO:0030906). GO:0030906 is a cellular component from the Gene Ontology.
Show evidence (3 references)
PMID:23452853 SUPPORT In Vitro
"ligase, MAGE-L2-TRIM27, localizes to endosomes through interactions with the retromer complex."
Establishes MAGEL2's molecular role in retromer-associated endosomal trafficking, whose loss is the proposed cell-biological defect in SYS.
PMID:23452853 SUPPORT In Vitro
"We further demonstrate that MAGE-L2-TRIM27 ubiquitin ligase activity is required for nucleation of endosomal F-actin by the WASH regulatory complex, a known regulator of retromer-mediated transport."
Defines the WASH-ubiquitination step through which MAGEL2 controls endosomal recycling.
PMID:23452853 SUPPORT In Vitro
"WASH ubiquitination was K63-linked, as WASH was unable to be polyubiquitinated by K63R ubiquitin"
Establishes the linkage type of the MAGE-L2-TRIM27 modification on WASH, supporting the GO:0070534 (protein K63-linked ubiquitination) annotation on this node.
Hypothalamic Oxytocin Deficiency
MAGEL2 is highly expressed in hypothalamic oxytocin-producing nuclei. Magel2-deficient neonatal mice have reduced hypothalamic oxytocin and a lethal suckling/feeding deficit that is recapitulated by an oxytocin-receptor antagonist and rescued by a single early postnatal oxytocin injection, implicating oxytocin deficiency in the neonatal feeding failure of SYS/PWS.
MAGEL2 Loss-of-Function Branch
oxytocin production GO:0036162 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves oxytocin production (GO:0036162). GO:0036162 is a biological process from the Gene Ontology.
Downstream
Neonatal Suckling and Feeding Failure MAGEL2 Loss-of-Function Branch
Show evidence (2 references)
PMID:20876615 SUPPORT Model Organism
"injection of a specific OT receptor antagonist in wild-type neonates recapitulated the feeding deficiency seen in Magel2 mutants"
Pharmacologic recapitulation and rescue link hypothalamic oxytocin deficiency to the neonatal feeding failure.
PMID:38396741 SUPPORT Other
"Oxytocin (Oxt) regulates thermogenesis, and altered thermoregulation results in Prader-Willi syndrome (PWS), Schaaf-Yang syndrome (SYS), and Autism spectrum disorder (ASD)."
Graded PARTIAL and tagged OTHER because this is a narrative review advancing a proposed hypothesis rather than reporting primary data: the authors explicitly "formulate a new hypothesis" linking disrupted oxytocin thermoregulation to SYS. It corroborates hypothalamic oxytocin as the affected system in SYS, but the thermoregulatory arm is not established, consistent with this node's PROVISIONAL mechanism_confidence.
Neonatal Suckling and Feeding Failure
Impaired suck and neonatal feeding difficulty is one of the earliest and most consistent manifestations, frequently requiring special feeding techniques or tube feeding, and contributing to failure to thrive in infancy.
regulation of feeding behavior GO:0060259 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves regulation of feeding behavior (GO:0060259). GO:0060259 is a biological process from the Gene Ontology.
Downstream
Feeding Difficulties in Infancy
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Gastrointestinal/feeding problems are particularly pronounced in infancy and childhood, but can transition to hyperphagia and obesity in adulthood."
GeneReviews describes the biphasic feeding course beginning with infantile feeding problems.
Progressive Hypothalamic Leptin Resistance
In the Magel2-null mouse, arcuate POMC neurons progressively lose leptin responsiveness after the neonatal period, providing a mechanism by which early feeding difficulty can give way to later hyperphagia and excessive weight gain in the subset of individuals who develop obesity.
Downstream
Excessive Weight Gain and Obesity
Show evidence (1 reference)
PMID:25926624 SUPPORT Model Organism
"Adult mice lacking Magel2 are insensitive to the anorexic effect of leptin treatment, and their hypothalamic pro-opiomelanocortin (POMC) neurons fail to depolarize in response to leptin."
Progressive hypothalamic leptin resistance provides a mechanistic basis for later-onset hyperphagia/obesity.
Reduced Fetal Movement and Distal Contracture Formation
At the severe end of the spectrum, MAGEL2 truncation reduces fetal movement, producing multiple distal joint contractures; complete loss of fetal movement manifests as arthrogryposis multiplex congenita and fetal akinesia. Paternal-allele mutant MAGEL2 transcripts are detected only in affected individuals, confirming the imprinted disease mechanism in these cases.
Downstream
Distal Joint Contractures
Fetal Akinesia and Arthrogryposis Multiplex Congenita
Show evidence (2 references)
PMID:26365340 SUPPORT Human Clinical
"Arthrogryposis multiplex congenita (AMC) is characterized by the presence of multiple joint contractures resulting from reduced or absent fetal movement."
Defines the reduced-fetal-movement mechanism that produces the contracture phenotype seen with MAGEL2 truncation.
PMID:26365340 SUPPORT Human Clinical
"In both families, RNA analysis identified the mutated paternal MAGEL2 transcripts only in affected individuals."
Confirms the paternal-allele, imprinted mechanism in the arthrogryposis cases.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Schaaf-Yang Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

25
Digestive 3
Feeding Difficulties in Infancy FREQUENT HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Gastrointestinal/feeding problems are particularly pronounced in infancy and childhood, but can transition to hyperphagia and obesity in adulthood."
GeneReviews describes prominent infantile feeding problems.
Gastroesophageal Reflux FREQUENT HP:0002020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27195816 SUPPORT Human Clinical
"Sleep apnea, gastroesophageal reflux, and decreased fetal movement are frequently reported in SHFYNG."
Direct qualitative frequency statement for gastroesophageal reflux in SHFYNG. Per the frequency-evidence guidelines, "frequently reported" maps to the FREQUENT band.
PMID:33570896 SUPPORT Human Clinical
"standard therapy for gastroesophageal reflux disease, metabolic syndrome, constipation, skeletal abnormalities, low bone mineral density, developmental delay/cognitive impairment, seizures, eye anomalies, undescended testes, hypogonadism and pubertal abnormalities, and hypothyroidism."
GeneReviews names gastroesophageal reflux disease among the manifestations requiring standard therapy in Schaaf-Yang syndrome.
Constipation HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
No frequency band asserted: the GeneReviews management and surveillance sentences establish that constipation occurs and is monitored, but neither reports a rate, and no count is available in the cited cohort.
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"standard therapy for gastroesophageal reflux disease, metabolic syndrome, constipation, skeletal abnormalities, low bone mineral density, developmental delay/cognitive impairment, seizures, eye anomalies, undescended testes, hypogonadism and pubertal abnormalities, and hypothyroidism."
GeneReviews names constipation among the manifestations requiring standard therapy in Schaaf-Yang syndrome.
PMID:33570896 SUPPORT Human Clinical
"monitor for signs and symptoms of constipation, sleep apnea, respiratory insufficiency, scoliosis, progression of contractures, and puberty"
Constipation is an explicit item on the GeneReviews surveillance schedule, corroborating it as a recurrent manifestation rather than an incidental finding.
Endocrine 3
Hypogonadotropic hypogonadism HP:0000044 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogonadotropic hypogonadism (HP:0000044). HP:0000044 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27195816 SUPPORT Human Clinical
"In addition, Patient 18 (Table S3) is a 20-year-old female diagnosed with hypogonadotropic hypogonadism."
Direct report of hypogonadotropic (central) hypogonadism in a molecularly confirmed Schaaf-Yang individual.
PMID:27195816 SUPPORT Human Clinical
"She was diagnosed with hypogonadotropic hypogonadism and presented dysmorphic labial development, identifiable upon pubertal maturation."
Recorded as PARTIAL because the same passage states she is the only female reported with hypogonadism to date and that no systematic endocrinological assessment of the syndrome has been reported, so the frequency and consistency of the hypogonadotropic mechanism are not established. No frequency band is asserted for this reason.
Hypogonadism FREQUENT HP:0000135 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogonadism (HP:0000135). HP:0000135 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"Other findings may include short stature, seizures, eye anomalies, and hypogonadism."
GeneReviews lists hypogonadism among additional findings.
PMID:27195816 SUPPORT Human Clinical
"Hypogonadism in the form of cryptorchidism and/or micropenis was present in 8 of 11 male cases and represents one of the earliest recognized physical features right after birth."
Sources the FREQUENT band by derived count: 8/11 male cases (73%) in this cohort, which falls in the 30-79% band. Note the denominator is male cases only; female hypogonadism is separately reported in this cohort as recognized in just one individual, so the cohort-wide rate is not established.
Hypothyroidism HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
No frequency band asserted: GeneReviews names hypothyroidism as a managed manifestation but reports no rate, and the cited cohort provides no count. A systematic endocrinological assessment of SHFYNG has not been reported.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"standard therapy for gastroesophageal reflux disease, metabolic syndrome, constipation, skeletal abnormalities, low bone mineral density, developmental delay/cognitive impairment, seizures, eye anomalies, undescended testes, hypogonadism and pubertal abnormalities, and hypothyroidism."
GeneReviews names hypothyroidism among the manifestations requiring standard therapy in Schaaf-Yang syndrome.
Genitourinary 1
Cryptorchidism FREQUENT HP:0000028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cryptorchidism (HP:0000028). HP:0000028 is a phenotype from the Human Phenotype Ontology.
The 8/11 count below is for cryptorchidism and/or micropenis combined, so it is an upper bound on cryptorchidism alone; the FREQUENT band is retained because the source also identifies it as one of the earliest recognized features in males, but a cryptorchidism-specific rate is not established.
Show evidence (2 references)
PMID:27195816 SUPPORT Human Clinical
"Hypogonadism in the form of cryptorchidism and/or micropenis was present in 8 of 11 male cases and represents one of the earliest recognized physical features right after birth."
Establishes cryptorchidism as a common early feature in affected males, with 8/11 male cases (73%) showing cryptorchidism and/or micropenis.
PMID:33570896 SUPPORT Human Clinical
"standard therapy for gastroesophageal reflux disease, metabolic syndrome, constipation, skeletal abnormalities, low bone mineral density, developmental delay/cognitive impairment, seizures, eye anomalies, undescended testes, hypogonadism and pubertal abnormalities, and hypothyroidism."
GeneReviews names undescended testes among the manifestations requiring standard therapy.
Head and Neck 1
Facial Dysmorphism VERY_FREQUENT Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Facial dysmorphism, annotated with Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"Of 18 molecularly confirmed postnatal cases, 16 are described to have a spectrum of varying facial dysmorphisms including malformations of the philtrum, ear position, nasal structure, frontal bossing and palpebral fissure length."
Sources the VERY_FREQUENT band by derived count: 16/18 cases (89%) had facial dysmorphism, which falls in the 80-99% band. HP:0001999 Abnormal facial shape is the generic parent term; the source describes a variable combination of features rather than one consistent gestalt, so no more specific term is asserted.
Limbs 2
Small Hands VERY_FREQUENT HP:0200055 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Small hand (HP:0200055). HP:0200055 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"A further assessment of skeletal features showed 12 of 14 cases to have small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small stature."
Sources the VERY_FREQUENT band by derived count: 12/14 cases (86%) had small hands, which falls in the 80-99% band.
Small Feet FREQUENT Short foot HP:0001773 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Small feet, annotated with Short foot (HP:0001773). HP:0001773 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"A further assessment of skeletal features showed 12 of 14 cases to have small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small stature."
Sources the FREQUENT band by derived count: 8/15 cases (53%) had small feet, which falls in the 30-79% band. HP:0001773 Short foot is the closest available term, so preferred_term retains the source's "small feet" wording.
Musculoskeletal 3
Neonatal Hypotonia OBLIGATE HP:0001319 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal hypotonia (HP:0001319), qualified as congenital onset. HP:0001319 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"It usually manifests at birth with muscular hypotonia in all and distal joint contractures in a majority of affected individuals."
GeneReviews states muscular hypotonia is present at birth in all affected individuals.
PMID:27195816 SUPPORT Human Clinical
"Developmental delay, intellectual disability, and hypotonia represent the most common phenotypes, present among all individuals for whom this information has been available"
The 18-individual cohort corroborates hypotonia as present in all assessed individuals.
Scoliosis FREQUENT HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Skeletal manifestations such as joint contractures, scoliosis, and decreased bone mineral density are frequently observed."
GeneReviews lists scoliosis among frequently observed skeletal manifestations.
Decreased Bone Mineral Density FREQUENT Reduced bone mineral density HP:0004349 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Skeletal manifestations such as joint contractures, scoliosis, and decreased bone mineral density are frequently observed."
GeneReviews lists decreased bone mineral density among frequently observed skeletal manifestations.
Nervous System 6
Developmental Delay and Intellectual Disability OBLIGATE HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"All affected individuals show developmental delay, resulting in intellectual disability of variable degree, from low-normal intelligence to severe intellectual disability."
GeneReviews states all affected individuals have developmental delay and intellectual disability.
PMID:27195816 SUPPORT Human Clinical
"Developmental delay, intellectual disability, and hypotonia represent the most common phenotypes, present among all individuals for whom this information has been available"
The 18-individual cohort corroborates DD/ID as present in all assessed individuals.
Autism Spectrum Disorder FREQUENT Autistic behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24076603 SUPPORT Human Clinical
"All four subjects had autism spectrum disorder (ASD), intellectual disability and a varying degree of clinical and behavioral features of PWS."
The discovery cohort documents ASD in all affected individuals.
PMID:38950199 SUPPORT Human Clinical
"Schaaf-Yang syndrome (SYS) is a complex neurodevelopmental disorder characterized by autism spectrum disorder, joint contractures, and profound hypothalamic dysfunction."
A review lists ASD as a defining feature of SYS.
Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Other findings may include short stature, seizures, eye anomalies, and hypogonadism."
GeneReviews lists seizures among additional findings.
Sleep Apnea FREQUENT HP:0010535 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep apnea (HP:0010535). HP:0010535 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:30238631 SUPPORT Human Clinical
"Here, we present an infant with SYS who sadly died because of the combination of hypotonia, sleep apnea, and obesity."
Documents sleep apnea as a contributor to SYS morbidity/mortality.
PMID:27195816 SUPPORT Human Clinical
"Sleep abnormalities were commonly seen, with 9 of 13 cases diagnosed with sleep apnea."
Sources the FREQUENT band by derived count: 9/13 cases (69%) were diagnosed with sleep apnea, which falls in the 30-79% band.
Impulsive and Compulsive Behavioral Profile VERY_FREQUENT Atypical behavior HP:0000708 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Impulsive, compulsive, stubborn, and manipulative behaviors, annotated with Atypical behavior (HP:0000708). HP:0000708 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"An analysis of patient behavior identified a spectrum of abnormalities, including impulsive, compulsive, stubborn, and manipulative behaviors (seen in nine of 11 cases for which this information was available)."
Sources the VERY_FREQUENT band by derived count: 9/11 assessed cases (82%) showed the behavioral spectrum, which falls in the 80-99% band. The count is reported for the spectrum as a whole, so it is modeled as one node under the generic HP:0000708 rather than split across HP:0000722 Compulsive behaviors and HP:0100710 Impulsivity, which would wrongly assign the combined 9/11 frequency to each component.
Habitual Skin Picking FREQUENT Self-injurious behavior HP:0100716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Habitual skin picking / automutilation, annotated with Self-injurious behavior (HP:0100716). HP:0100716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"Parents reported habitual skin picking or automutilation of varying severity in seven of 12 molecularly diagnosed individuals."
Sources the FREQUENT band by derived count: 7/12 cases (58%) had habitual skin picking, which falls in the 30-79% band. The finding is parent-reported rather than systematically ascertained.
Respiratory 1
Neonatal Respiratory Distress FREQUENT HP:0002643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal respiratory distress (HP:0002643), qualified as congenital onset. HP:0002643 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Respiratory distress is present in many individuals at birth, with approximately half requiring intubation and mechanical ventilation, and approximately 20% requiring tracheostomy."
GeneReviews quantifies the frequency and severity of neonatal respiratory distress.
Growth 2
Excessive Weight Gain and Obesity FREQUENT HP:0001513 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:27195816 SUPPORT Human Clinical
"only eight of 17 molecularly confirmed individuals had excessive weight gain, typically associated with PWS"
Derived count: 8/17 molecularly confirmed individuals (47%) had excessive weight gain, which falls in the HPO FREQUENT band (30-79%). The same sentence's surrounding text notes most individuals do not reach the hyperphagic phase, which is why the phenotype is scoped to weight gain/obesity.
PMID:33570896 SUPPORT Human Clinical
"but can transition to hyperphagia and obesity in adulthood"
GeneReviews notes the transition to hyperphagia and obesity in a subset.
PMID:30238631 SUPPORT Human Clinical
"Our clinical report indicates that obesity and its complications are an important additional factor in the mortality associated with SYS."
A clinical report links obesity to SYS mortality.
Short Stature FREQUENT HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"Other findings may include short stature, seizures, eye anomalies, and hypogonadism."
GeneReviews lists short stature among additional findings.
PMID:27195816 SUPPORT Human Clinical
"A further assessment of skeletal features showed 12 of 14 cases to have small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small stature."
Sources the FREQUENT band by derived count: 10/16 cases (63%) had small stature, which falls in the 30-79% band.
Other 3
Distal Joint Contractures FREQUENT Distal arthrogryposis HP:0005684 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Distal arthrogryposis (HP:0005684). HP:0005684 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"It usually manifests at birth with muscular hypotonia in all and distal joint contractures in a majority of affected individuals."
GeneReviews states distal joint contractures occur in a majority of affected individuals.
PMID:27195816 SUPPORT Human Clinical
"The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia to neurobehavioral disease and contractures of the small finger joints."
Fountain et al. document small-finger-joint contractures as part of the spectrum.
Eye Abnormalities FREQUENT Abnormality of the eye HP:0000478 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eye abnormality, annotated with Abnormality of the eye (HP:0000478). HP:0000478 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"Eleven of 14 patients manifested eye abnormalities in the form of strabismus, esotropia, or myopia."
Derived count: 11/14 patients (79%) had eye abnormalities in the largest phenotyping series, placing this in the HPO FREQUENT band (30-79%). The generic HP:0000478 term is used because the source bundles strabismus, esotropia, and myopia without per-finding counts.
Fetal Akinesia and Arthrogryposis Multiplex Congenita Fetal akinesia sequence HP:0001989 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fetal akinesia sequence (HP:0001989), qualified as antenatal onset. HP:0001989 is a phenotype from the Human Phenotype Ontology.
Onset: ANTENATAL
Show evidence (2 references)
PMID:26365340 SUPPORT Human Clinical
"Here, we show that paternal MAGEL2 mutations are also responsible for lethal AMC, recapitulating the clinical spectrum of PWS"
Establishes lethal arthrogryposis / fetal akinesia at the severe end of the MAGEL2 spectrum.
PMID:27195816 SUPPORT Human Clinical
"The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia to neurobehavioral disease and contractures of the small finger joints."
Places fetal akinesia at the severe end of the SYS spectrum.
🧬

Genetic Associations

1
MAGEL2
Gene: MAGEL2 hgnc:6814 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MAGEL2 (hgnc:6814). hgnc:6814 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:27195816 SUPPORT Human Clinical
"All cases harbor truncating mutations of MAGEL2, and nucleotides c.1990-1996 arise as a mutational hotspot, with 10 individuals and 1 fetus harboring a c.1996dupC (p.Q666fs) mutation"
Documents the truncating-variant class and the c.1996 mutational hotspot.
💊

Medical Actions

5
Feeding Therapy and Supplemental Tube Feeding
Action: gastrostomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gastrostomy (NCIT:C52006). NCIT:C52006 is a clinical intervention from the NCI Thesaurus. Ontology label: Gastrostomy NCIT:C52006
Feeding therapy or supplemental (naso-gastric or gastrostomy) tube feeding is used for persistent infantile feeding difficulties and failure to thrive.
Mechanism Target:
BYPASSES Neonatal Suckling and Feeding Failure — Tube feeding does not correct the suckling deficit; it delivers nutrition through an alternative route, working around the disrupted mechanism.
Target Phenotypes: Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Feeding therapy or supplemental tube feeding may be required for persistent feeding issues"
GeneReviews management recommends feeding therapy / tube feeding.
Oxytocin (Experimental)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: oxytocin CHEBI:7872 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses oxytocin (CHEBI:7872). CHEBI:7872 is a therapeutic agent from Chemical Entities of Biological Interest.
Early postnatal oxytocin administration is an experimental, preclinical strategy aimed at the hypothalamic oxytocin deficiency itself rather than at compensating for its consequences. In Magel2-deficient mice a single injection 3-5 hours after birth rescued the otherwise lethal suckling failure. This is NOT established human therapy for Schaaf-Yang syndrome: the supporting evidence is model-organism only, the authors' clinical proposal is framed for Prader-Willi neonates, and GeneReviews management does not include it.
Mechanism Target:
RESTORES Hypothalamic Oxytocin Deficiency — Exogenous oxytocin replaces the deficient hypothalamic oxytocin signal, restoring the suckling behaviour lost in Magel2-deficient neonates.
Target Phenotypes: Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20876615 SUPPORT Model Organism
"a single injection of OT, 3-5 h after birth, rescued the phenotype of Magel2 mutant pups, allowing all of them to survive"
Preclinical proof of concept for oxytocin as a mechanism-directed therapy: a single postnatal injection rescued the lethal phenotype in the mouse model. Model-organism evidence only, which is why this treatment is labelled experimental and carries no human efficacy claim.
PMID:20876615 SUPPORT Model Organism
"We propose that OT supply might constitute a promising avenue for the treatment of feeding difficulties in PW neonates"
The authors' own therapeutic proposal, graded PARTIAL because it is explicitly a proposal ("might constitute a promising avenue") and is framed for Prader-Willi neonates rather than Schaaf-Yang syndrome. The read-across rests on shared MAGEL2 involvement, so it supports the hypothesis but not clinical use in SYS.
Assisted Ventilation and CPAP
Action: artificial respirationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is artificial respiration, annotated with Mechanical Ventilation (NCIT:C70909). NCIT:C70909 is a clinical intervention from the NCI Thesaurus. Ontology label: Mechanical Ventilation NCIT:C70909
Assisted ventilation (noninvasive or invasive) is used for neonatal respiratory distress, and CPAP is used for sleep apnea.
Target Phenotypes: Neonatal respiratory distress HP:0002643 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Neonatal respiratory distress (HP:0002643). HP:0002643 is a phenotype from the Human Phenotype Ontology. Sleep apnea HP:0010535 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sleep apnea (HP:0010535). HP:0010535 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"assisted ventilation to include either noninvasive or invasive intervention; CPAP for sleep apnea"
GeneReviews management recommends assisted ventilation and CPAP.
Growth Hormone Therapy
Action: human growth hormone replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is human growth hormone replacement therapy, annotated with Hormone Replacement Therapy (NCIT:C15599). NCIT:C15599 is a clinical intervention from the NCI Thesaurus. Ontology label: Hormone Replacement Therapy NCIT:C15599
Growth hormone therapy is used in individuals with short stature and/or linear-growth concerns; polysomnography is recommended for those on long-term GH therapy.
Target Phenotypes: Short stature HP:0004322 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"growth hormone therapy in those with short stature and/or linear growth concerns"
GeneReviews management recommends GH therapy for short stature.
Physical Therapy for Contractures
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Physical therapy and orthopedic management address joint contractures, progression of contractures, and scoliosis.
Target Phenotypes: Distal arthrogryposis HP:0005684 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Distal arthrogryposis (HP:0005684). HP:0005684 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"monitor for signs and symptoms of constipation, sleep apnea, respiratory insufficiency, scoliosis, progression of contractures, and puberty"
GeneReviews surveillance targets contractures and scoliosis, managed with physical/orthopedic therapy.
🔬

Biochemical Markers

3
Secreted Amyloid-beta 1-40 (Abeta1-40) (decreased)
Show evidence (2 references)
PMID:36243518 SUPPORT In Vitro
"Functional studies show significantly decreased levels of secreted Aβ1-40 and intracellular glutamine in SYS fibroblasts compared with WT."
Establishes reduced secreted Abeta1-40 in patient fibroblasts versus wild-type controls.
PMID:36243518 SUPPORT In Vitro
"Aβ1-40 secretion levels and HOTAIR mRNA levels might be promising biomarkers for SYS."
The authors propose Abeta1-40 secretion as a candidate biomarker, stated as a possibility rather than a validated one.
Intracellular Glutamine (decreased)
Show evidence (1 reference)
PMID:36243518 SUPPORT In Vitro
"Functional studies show significantly decreased levels of secreted Aβ1-40 and intracellular glutamine in SYS fibroblasts compared with WT."
Establishes reduced intracellular glutamine in patient fibroblasts versus wild-type controls.
HOTAIR Long Non-Coding RNA
Show evidence (2 references)
PMID:36243518 SUPPORT In Vitro
"We also identified 132 differentially expressed genes, including non-coding RNAs (ncRNAs) such as HOTAIR, and many of them related to developmental processes and mitotic mechanisms."
Identifies HOTAIR as differentially expressed in patient fibroblasts.
PMID:36243518 SUPPORT In Vitro
"Aβ1-40 secretion levels and HOTAIR mRNA levels might be promising biomarkers for SYS."
The authors propose HOTAIR mRNA level as a candidate biomarker, stated as a possibility rather than a validated one.
🔬

Diagnosis

2
Molecular Genetic Testing of MAGEL2
The diagnosis is established by identifying a heterozygous pathogenic variant on the paternally derived MAGEL2 allele. Because MAGEL2 is maternally imprinted, determining the parental origin of the variant is required to interpret the result, and parental testing is important for counseling.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:33570896 SUPPORT Human Clinical
"The diagnosis of Schaaf-Yang syndrome is established in a proband by identification of a heterozygous pathogenic variant in the paternally derived MAGEL2 allele by molecular genetic testing."
GeneReviews states the molecular diagnostic criterion for Schaaf-Yang syndrome.
PMID:27195816 SUPPORT Human Clinical
"The familial association highlights the importance of parental testing, determination of the allelic location of the mutation, and the challenges for genetic counseling."
Supports parental testing and allelic-origin determination as part of the diagnostic workup, which follows from the imprinted inheritance.
MAGEL2 Testing After Negative Prader-Willi Methylation Analysis
Schaaf-Yang syndrome is a principal differential diagnosis of Prader-Willi syndrome. MAGEL2 testing should be considered in a PWS-like phenotype with negative PWS methylation analysis. Neonatal contractures favor Schaaf-Yang syndrome, whereas childhood-onset hyperphagia is more characteristic of Prader-Willi syndrome, though no single feature is exclusive to either.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:27195816 SUPPORT Human Clinical
"Given the phenotypic overlap between PWS and SHFYNG, testing for mutations in MAGEL2 should be considered in the context of PWS-like phenotypes, but negative PWS methylation analysis."
States the diagnostic trigger for MAGEL2 testing: a PWS-like phenotype with negative PWS methylation analysis.
PMID:27195816 SUPPORT Human Clinical
"While SHFYNG and PWS share an appreciable amount of common features, and no specific feature appears to be exclusive of one or the other condition, the presence of contractures at birth makes SHFYNG more likely, while the development of hyperphagia in childhood appears to be more characteristic of PWS."
Provides the discriminating clinical features between Schaaf-Yang and Prader-Willi syndrome, while noting that no feature is exclusive.
📊

Prevalence

1
Worldwide
Cases In Literature Unknown
SYS is exceptionally rare and literature-defined; population prevalence and incidence remain undetermined.
Show evidence (1 reference)
PMID:33570896 SUPPORT Human Clinical
"Schaaf-Yang syndrome (SYS) is a rare neurodevelopmental disorder that shares multiple clinical features with the genetically related Prader-Willi syndrome."
GeneReviews classifies SYS as a rare disorder; population prevalence and incidence are not established, consistent with an ultra-rare, literature-defined disorder.
{ }

Source YAML

click to show 
name: Schaaf-Yang Syndrome
creation_date: "2026-07-29T00:00:00Z"
synonyms:
- SYS
- SHFYNG
- Prader-Willi-like syndrome due to MAGEL2 mutation
- MAGEL2-related Schaaf-Yang syndrome
description: >-
  Schaaf-Yang syndrome (SYS; OMIM 615547) is a rare autosomal dominant,
  maternally imprinted neurodevelopmental disorder caused by truncating
  pathogenic variants in the paternally expressed allele of MAGEL2, one of the
  protein-coding genes within the Prader-Willi critical region at 15q11-q13.
  Because MAGEL2 is maternally imprinted, only the paternally derived allele is
  transcribed, so a truncating variant on that allele (whether paternally
  inherited or a de novo variant on the paternal chromosome) leaves the
  individual without functional MAGEL2. SYS shares many features with the
  genetically related Prader-Willi syndrome — neonatal hypotonia, feeding
  difficulties that can transition to hyperphagia and obesity, developmental
  delay, and hypogonadism — but is clinically distinguished by a high frequency
  of distal joint contractures (ranging to arthrogryposis multiplex congenita
  and fetal akinesia at the severe end) and a strikingly elevated rate of autism
  spectrum disorder and more severe intellectual disability. MAGEL2 encodes a
  single-exon MAGE-family protein that scaffolds the MAGE-L2-TRIM27 ubiquitin
  ligase governing WASH-dependent, retromer-mediated endosomal protein recycling,
  and it modulates hypothalamic oxytocin and neuroendocrine systems. The
  prevailing model combines loss of MAGEL2 function with a possible neomorphic
  or toxic effect of the stable, nuclear-mislocalized truncated protein, since
  whole-gene deletions of paternal MAGEL2 produce little or no phenotype.
category: Mendelian
disease_term:
  preferred_term: Schaaf-Yang syndrome
  term:
    id: MONDO:0014243
    label: Schaaf-Yang syndrome
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    SYS is inherited in an autosomal dominant, maternally imprinted manner: a
    heterozygous pathogenic variant on the paternally derived MAGEL2 allele
    causes disease, whereas the same variant on the maternally derived allele
    does not, because the maternal MAGEL2 allele is normally silenced.
    Approximately half of affected individuals inherited the variant from a
    clinically unaffected father, and the remainder are de novo.
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Schaaf-Yang syndrome is inherited in an autosomal dominant, maternally
      imprinted manner (i.e., a heterozygous pathogenic variant on the
      paternally derived MAGEL2 allele results in disease; a pathogenic variant
      on the maternally derived MAGEL2 allele does not result in disease because
      normally the maternally derived MAGEL2 allele is silenced).
    explanation: >-
      GeneReviews states the autosomal dominant, maternally imprinted mode of
      inheritance.
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 50% of individuals diagnosed with SYS inherited a MAGEL2
      pathogenic variant from a clinically unaffected father and the remainder
      are de novo.
    explanation: >-
      GeneReviews quantifies the inherited-versus-de-novo split, reflecting the
      maternal imprinting of MAGEL2.
  penetrance: UNKNOWN
  expressivity: VARIABLE
parents:
- autosomal dominant syndromic intellectual disability
- autism spectrum disorder

references:
- reference: PMID:33570896
  title: "Schaaf-Yang Syndrome."
  tags:
  - GeneReviews
- reference: PMID:24076603
  title: "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism."
- reference: PMID:26365340
  title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
- reference: PMID:27195816
  title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
- reference: PMID:30238631
  title: "The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation."
- reference: PMID:23452853
  title: "Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination."
- reference: PMID:20876615
  title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
- reference: PMID:25926624
  title: "Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome."
- reference: PMID:36243518
  title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
- reference: PMID:38950199
  title: "MAGEL2 (patho-)physiology and Schaaf-Yang syndrome."
- reference: PMID:38396741
  title: "The Pivotal Role of Oxytocin's Mechanism of Thermoregulation in Prader-Willi Syndrome, Schaaf-Yang Syndrome, and Autism Spectrum Disorder."

mechanistic_hypotheses:
- hypothesis_group_id: magel2_loss_of_function
  hypothesis_label: MAGEL2 Loss-of-Function Branch
  status: CANONICAL
  description: >-
    Because MAGEL2 is expressed only from the paternal allele, a truncating
    variant on that allele leaves the individual with no functional MAGEL2
    protein (functional hemizygosity). Loss of MAGEL2's role in
    retromer/WASH-dependent endosomal recycling and hypothalamic neuroendocrine
    regulation is proposed to underlie many SYS (and shared PWS) phenotypes.
  evidence:
  - reference: PMID:24076603
    reference_title: "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given the functional hemizygosity for this gene, a truncating mutation on
      the paternal allele leaves affected individuals without functional,
      expressed MAGEL2, making it potentially pathogenic.
    explanation: >-
      The discovery paper frames SYS as loss of functional MAGEL2 owing to
      paternal-allele functional hemizygosity.
- hypothesis_group_id: truncated_protein_neomorphic
  hypothesis_label: Neomorphic Truncated-Protein Branch
  status: EMERGING
  description: >-
    Loss of function alone does not fully explain SYS, because whole-gene
    deletions of paternal MAGEL2 produce little or no phenotype whereas
    truncating variants cause disease. Patient-derived and cell-based studies
    show that the truncated MAGEL2 protein is stable and mislocalizes to the
    nucleus, suggesting an additional neomorphic/toxic gain-of-function
    contribution beyond simple haploinsufficiency.
  evidence:
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The truncated form of MAGEL2 displayed a stability similar to the WT but
      it was significantly switched to the nucleus, compared with a mainly
      cytoplasmic distribution of the WT MAGEL2.
    explanation: >-
      Nuclear mislocalization of a stable truncated protein supports a
      neomorphic mechanism distinct from a simple null.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the pathogenicity of truncating mutations of the paternal allele of
      MAGEL2 has been questioned, due to the small number of cases reported, but
      also because whole-gene deletions of the paternal copy of MAGEL2 appear to
      have no phenotype or very mild phenotypes.
    explanation: >-
      The deletion-versus-truncation discrepancy is the clinical observation
      motivating a non-null (neomorphic) contribution.

pathophysiology:
- name: MAGEL2 Truncating Variant on the Expressed Paternal Allele
  description: >-
    The initiating lesion is a truncating (nonsense or frameshift) pathogenic
    variant in MAGEL2 on the paternally expressed allele. MAGEL2 is a single-exon
    gene within the maternally imprinted Prader-Willi region at 15q11-q13, so
    only the paternal allele is transcribed; a truncating variant on that allele
    removes the C-terminal MAGE homology domain from the expressed protein.
  mechanism_confidence: ESTABLISHED
  biological_scale: MOLECULAR
  genes:
  - preferred_term: MAGEL2
    term:
      id: hgnc:6814
      label: MAGEL2
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of Schaaf-Yang syndrome is established in a proband by
      identification of a heterozygous pathogenic variant in the paternally
      derived MAGEL2 allele by molecular genetic testing.
    explanation: >-
      GeneReviews establishes that a variant on the paternally derived MAGEL2
      allele is the molecular cause.
  downstream:
  - target: Loss of Functional MAGEL2 Protein
    causal_link_type: DIRECT
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:24076603
      reference_title: "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Given the functional hemizygosity for this gene, a truncating mutation
        on the paternal allele leaves affected individuals without functional,
        expressed MAGEL2, making it potentially pathogenic.
      explanation: >-
        Paternal-allele functional hemizygosity means one truncating variant
        abolishes functional MAGEL2.
  - target: Stable Nuclear-Mislocalized Truncated MAGEL2
    causal_link_type: DIRECT
    hypothesis_groups:
    - truncated_protein_neomorphic
    evidence:
    - reference: PMID:36243518
      reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The truncated form of MAGEL2 displayed a stability similar to the WT but
        it was significantly switched to the nucleus, compared with a mainly
        cytoplasmic distribution of the WT MAGEL2.
      explanation: >-
        Truncating variants yield a stable protein that mislocalizes to the
        nucleus rather than a simple null product.

- name: Loss of Functional MAGEL2 Protein
  description: >-
    With no functional MAGEL2 expressed, the MAGE-L2-TRIM27 ubiquitin-ligase
    scaffold that normally supports endosomal protein recycling and hypothalamic
    neuroendocrine function is lost. This loss-of-function is proposed to
    underlie phenotypes shared with Prader-Willi syndrome.
  mechanism_confidence: PROVISIONAL
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:38950199
    reference_title: "MAGEL2 (patho-)physiology and Schaaf-Yang syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      while MAGEL2 loss-of-function seems to underlie several SYS and PWS
      phenotypes, additional pathomechanisms probably contribute to the distinct
      and severe phenotype observed in SYS
    explanation: >-
      A current review attributes several phenotypes to MAGEL2 loss of function
      while noting additional mechanisms in SYS.
  downstream:
  - target: Impaired MAGE-L2-TRIM27 Endosomal Protein Recycling
    causal_link_type: DIRECT
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:23452853
      reference_title: "Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Knockdown of MAGE-L2-TRIM27 or the Ube2O E2 ubiquitin-conjugating enzyme
        significantly impaired retromer-mediated transport.
      explanation: >-
        Loss of MAGE-L2-TRIM27 activity impairs retromer-mediated endosomal
        transport in cells.
  - target: Hypothalamic Oxytocin Deficiency
    causal_link_type: DIRECT
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:20876615
      reference_title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The hypothalamus of Magel2 mutant neonates showed a significant
        reduction in oxytocin (OT).
      explanation: >-
        Magel2-deficient mice show reduced hypothalamic oxytocin, linking MAGEL2
        loss to neuroendocrine deficit.
  - target: Progressive Hypothalamic Leptin Resistance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:25926624
      reference_title: "Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Adult mice lacking Magel2 are insensitive to the anorexic effect of
        leptin treatment, and their hypothalamic pro-opiomelanocortin (POMC)
        neurons fail to depolarize in response to leptin.
      explanation: >-
        MAGEL2 loss produces progressive hypothalamic leptin resistance in the
        mouse model.
  - target: Neonatal Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        It usually manifests at birth with muscular hypotonia in all and distal
        joint contractures in a majority of affected individuals.
      explanation: >-
        MAGEL2 loss of function manifests as neonatal hypotonia in essentially
        all affected individuals.
  - target: Developmental Delay and Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All affected individuals show developmental delay, resulting in
        intellectual disability of variable degree, from low-normal intelligence
        to severe intellectual disability.
      explanation: >-
        MAGEL2 loss of function manifests as developmental delay / intellectual
        disability in all affected individuals.
  - target: Autism Spectrum Disorder
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24076603
      reference_title: "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All four subjects had autism spectrum disorder (ASD), intellectual
        disability and a varying degree of clinical and behavioral features of
        PWS.
      explanation: >-
        Truncating MAGEL2 variants manifest with autism spectrum disorder.
  - target: Neonatal Respiratory Distress
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Respiratory distress is present in many individuals at birth, with
        approximately half requiring intubation and mechanical ventilation, and
        approximately 20% requiring tracheostomy.
      explanation: >-
        MAGEL2 loss of function manifests as neonatal respiratory distress in
        many affected individuals.
  - target: Hypogonadism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other findings may include short stature, seizures, eye anomalies, and
        hypogonadism.
      explanation: >-
        Hypogonadism is part of the MAGEL2-loss neuroendocrine spectrum.
  - target: Short Stature
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other findings may include short stature, seizures, eye anomalies, and
        hypogonadism.
      explanation: >-
        Short stature is part of the MAGEL2-loss clinical spectrum.
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other findings may include short stature, seizures, eye anomalies, and
        hypogonadism.
      explanation: >-
        Seizures are part of the MAGEL2-loss clinical spectrum.
  - target: Scoliosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Skeletal manifestations such as joint contractures, scoliosis, and
        decreased bone mineral density are frequently observed.
      explanation: >-
        Scoliosis is a frequently observed skeletal manifestation of SYS.
  - target: Decreased Bone Mineral Density
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Skeletal manifestations such as joint contractures, scoliosis, and
        decreased bone mineral density are frequently observed.
      explanation: >-
        Decreased bone mineral density is a frequently observed skeletal
        manifestation of SYS.
  - target: Sleep Apnea
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30238631
      reference_title: "The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Here, we present an infant with SYS who sadly died because of the
        combination of hypotonia, sleep apnea, and obesity.
      explanation: >-
        Sleep apnea is part of the SYS respiratory/hypotonia phenotype.
  - target: Reduced Fetal Movement and Distal Contracture Formation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:26365340
      reference_title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Here, we show that paternal MAGEL2 mutations are also responsible for
        lethal AMC, recapitulating the clinical spectrum of PWS
      explanation: >-
        Loss of functional MAGEL2 reduces fetal movement, producing
        contractures/arthrogryposis at the severe end.
  - target: Facial Dysmorphism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Of 18 molecularly confirmed postnatal cases, 16 are described to have a
        spectrum of varying facial dysmorphisms including malformations of the
        philtrum, ear position, nasal structure, frontal bossing and palpebral
        fissure length.
      explanation: >-
        Facial dysmorphism is part of the MAGEL2-loss clinical spectrum.
  - target: Eye Abnormalities
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Eleven of 14 patients manifested eye abnormalities in the form of
        strabismus, esotropia, or myopia.
      explanation: >-
        Eye abnormalities are part of the MAGEL2-loss clinical spectrum.
  - target: Cryptorchidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hypogonadism in the form of cryptorchidism and/or micropenis was present
        in 8 of 11 male cases and represents one of the earliest recognized
        physical features right after birth.
      explanation: >-
        Cryptorchidism (a form of hypogonadism) reflects the MAGEL2-loss
        neuroendocrine spectrum.
  - target: Hypothyroidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        standard therapy for gastroesophageal reflux disease, metabolic
        syndrome, constipation, skeletal abnormalities, low bone mineral
        density, developmental delay/cognitive impairment, seizures, eye
        anomalies, undescended testes, hypogonadism and pubertal abnormalities,
        and hypothyroidism.
      explanation: >-
        Hypothyroidism is part of the MAGEL2-loss endocrine spectrum requiring
        standard therapy.
  - target: Gastroesophageal Reflux
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Sleep apnea, gastroesophageal reflux, and decreased fetal movement are
        frequently reported in SHFYNG.
      explanation: >-
        Gastroesophageal reflux is a frequently reported gastrointestinal
        manifestation of MAGEL2 loss.
  - target: Constipation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        standard therapy for gastroesophageal reflux disease, metabolic
        syndrome, constipation, skeletal abnormalities, low bone mineral
        density, developmental delay/cognitive impairment, seizures, eye
        anomalies, undescended testes, hypogonadism and pubertal abnormalities,
        and hypothyroidism.
      explanation: >-
        Constipation is part of the MAGEL2-loss gastrointestinal spectrum
        requiring standard therapy.
  - target: Small Hands
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A further assessment of skeletal features showed 12 of 14 cases to have
        small hands, 8 of 15 to have small feet, and 10 of 16 cases to have
        small stature.
      explanation: >-
        Small hands are part of the MAGEL2-loss skeletal spectrum.
  - target: Small Feet
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A further assessment of skeletal features showed 12 of 14 cases to have
        small hands, 8 of 15 to have small feet, and 10 of 16 cases to have
        small stature.
      explanation: >-
        Small feet are part of the MAGEL2-loss skeletal spectrum.
  - target: Impulsive and Compulsive Behavioral Profile
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        An analysis of patient behavior identified a spectrum of abnormalities,
        including impulsive, compulsive, stubborn, and manipulative behaviors
        (seen in nine of 11 cases for which this information was available).
      explanation: >-
        The impulsive/compulsive behavioral profile is part of the MAGEL2-loss
        neurobehavioral spectrum.
  - target: Habitual Skin Picking
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27195816
      reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Parents reported habitual skin picking or automutilation of varying
        severity in seven of 12 molecularly diagnosed individuals.
      explanation: >-
        Habitual skin picking is part of the MAGEL2-loss neurobehavioral
        spectrum.

- name: Stable Nuclear-Mislocalized Truncated MAGEL2
  description: >-
    Distinct from a simple null, the truncated MAGEL2 protein produced by SYS
    variants is stable and shifts to a predominantly nuclear distribution
    (versus the cytoplasmic wild-type). This supports a neomorphic/toxic
    gain-of-function contribution that may explain why truncating variants cause
    disease while whole-gene deletions largely do not, and is associated with
    altered fibroblast transcriptomic and metabolomic profiles.
  mechanism_confidence: PROVISIONAL
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We also identified 132 differentially expressed genes, including
      non-coding RNAs (ncRNAs) such as HOTAIR, and many of them related to
      developmental processes and mitotic mechanisms.
    explanation: >-
      Patient fibroblasts carrying truncated MAGEL2 show a distinct
      transcriptomic signature consistent with an active molecular consequence.

- name: Impaired MAGE-L2-TRIM27 Endosomal Protein Recycling
  description: >-
    MAGEL2 forms the substrate-recognition module of the MAGE-L2-TRIM27 RING
    ubiquitin ligase, which localizes to endosomes via the retromer and
    K63-ubiquitinates WASH to nucleate endosomal F-actin required for
    retromer-mediated cargo recycling. Loss of this activity impairs retrograde
    endosome-to-Golgi transport and recycling of surface receptors, disturbing
    neuronal and neuroendocrine cell function.
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: retrograde endosome-to-Golgi transport
    term:
      id: GO:0042147
      label: retrograde transport, endosome to Golgi
  - preferred_term: K63-linked ubiquitination of WASH by MAGE-L2-TRIM27
    term:
      id: GO:0070534
      label: protein K63-linked ubiquitination
    modifier: DECREASED
  cellular_components:
  - preferred_term: retromer cargo-selective complex
    term:
      id: GO:0030906
      label: retromer, cargo-selective complex
  evidence:
  - reference: PMID:23452853
    reference_title: "Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      ligase, MAGE-L2-TRIM27, localizes to endosomes through interactions with
      the retromer complex.
    explanation: >-
      Establishes MAGEL2's molecular role in retromer-associated endosomal
      trafficking, whose loss is the proposed cell-biological defect in SYS.
  - reference: PMID:23452853
    reference_title: "Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We further demonstrate that MAGE-L2-TRIM27 ubiquitin ligase activity is
      required for nucleation of endosomal F-actin by the WASH regulatory
      complex, a known regulator of retromer-mediated transport.
    explanation: >-
      Defines the WASH-ubiquitination step through which MAGEL2 controls
      endosomal recycling.
  - reference: PMID:23452853
    reference_title: "Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      WASH ubiquitination was K63-linked, as WASH was unable to be
      polyubiquitinated by K63R ubiquitin
    explanation: >-
      Establishes the linkage type of the MAGE-L2-TRIM27 modification on WASH,
      supporting the GO:0070534 (protein K63-linked ubiquitination) annotation
      on this node.

- name: Hypothalamic Oxytocin Deficiency
  description: >-
    MAGEL2 is highly expressed in hypothalamic oxytocin-producing nuclei.
    Magel2-deficient neonatal mice have reduced hypothalamic oxytocin and a
    lethal suckling/feeding deficit that is recapitulated by an oxytocin-receptor
    antagonist and rescued by a single early postnatal oxytocin injection,
    implicating oxytocin deficiency in the neonatal feeding failure of SYS/PWS.
  mechanism_confidence: PROVISIONAL
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: oxytocin production
    term:
      id: GO:0036162
      label: oxytocin production
  evidence:
  - reference: PMID:20876615
    reference_title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      injection of a specific OT receptor antagonist in wild-type neonates
      recapitulated the feeding deficiency seen in Magel2 mutants
    explanation: >-
      Pharmacologic recapitulation and rescue link hypothalamic oxytocin
      deficiency to the neonatal feeding failure.
  - reference: PMID:38396741
    reference_title: "The Pivotal Role of Oxytocin's Mechanism of Thermoregulation in Prader-Willi Syndrome, Schaaf-Yang Syndrome, and Autism Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Oxytocin (Oxt) regulates thermogenesis, and altered thermoregulation
      results in Prader-Willi syndrome (PWS), Schaaf-Yang syndrome (SYS), and
      Autism spectrum disorder (ASD).
    explanation: >-
      Graded PARTIAL and tagged OTHER because this is a narrative review
      advancing a proposed hypothesis rather than reporting primary data: the
      authors explicitly "formulate a new hypothesis" linking disrupted
      oxytocin thermoregulation to SYS. It corroborates hypothalamic oxytocin
      as the affected system in SYS, but the thermoregulatory arm is not
      established, consistent with this node's PROVISIONAL
      mechanism_confidence.
  downstream:
  - target: Neonatal Suckling and Feeding Failure
    causal_link_type: DIRECT
    hypothesis_groups:
    - magel2_loss_of_function
    evidence:
    - reference: PMID:20876615
      reference_title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        a Magel2-deficient mouse with 50% neonatal mortality had an altered
        onset of suckling activity and subsequent impaired feeding, suggesting a
        role of MAGEL2 in the suckling deficit seen in PW newborns.
      explanation: >-
        Magel2 loss causes a suckling/feeding deficit paralleling the human
        neonatal feeding difficulty.

- name: Neonatal Suckling and Feeding Failure
  description: >-
    Impaired suck and neonatal feeding difficulty is one of the earliest and
    most consistent manifestations, frequently requiring special feeding
    techniques or tube feeding, and contributing to failure to thrive in
    infancy.
  mechanism_confidence: ESTABLISHED
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: regulation of feeding behavior
    term:
      id: GO:0060259
      label: regulation of feeding behavior
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gastrointestinal/feeding problems are particularly pronounced in infancy
      and childhood, but can transition to hyperphagia and obesity in adulthood.
    explanation: >-
      GeneReviews describes the biphasic feeding course beginning with infantile
      feeding problems.
  downstream:
  - target: Feeding Difficulties in Infancy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Gastrointestinal/feeding problems are particularly pronounced in infancy
        and childhood, but can transition to hyperphagia and obesity in
        adulthood.
      explanation: >-
        Neonatal suckling/feeding failure manifests as prominent infantile
        feeding difficulties.

- name: Progressive Hypothalamic Leptin Resistance
  description: >-
    In the Magel2-null mouse, arcuate POMC neurons progressively lose leptin
    responsiveness after the neonatal period, providing a mechanism by which
    early feeding difficulty can give way to later hyperphagia and excessive
    weight gain in the subset of individuals who develop obesity.
  mechanism_confidence: PROVISIONAL
  biological_scale: TISSUE
  evidence:
  - reference: PMID:25926624
    reference_title: "Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Adult mice lacking Magel2 are insensitive to the anorexic effect of leptin
      treatment, and their hypothalamic pro-opiomelanocortin (POMC) neurons fail
      to depolarize in response to leptin.
    explanation: >-
      Progressive hypothalamic leptin resistance provides a mechanistic basis
      for later-onset hyperphagia/obesity.
  downstream:
  - target: Excessive Weight Gain and Obesity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        but can transition to hyperphagia and obesity in adulthood
      explanation: >-
        Progressive hypothalamic leptin resistance provides the mechanistic
        basis for later hyperphagia/obesity in a subset.

- name: Reduced Fetal Movement and Distal Contracture Formation
  description: >-
    At the severe end of the spectrum, MAGEL2 truncation reduces fetal movement,
    producing multiple distal joint contractures; complete loss of fetal
    movement manifests as arthrogryposis multiplex congenita and fetal akinesia.
    Paternal-allele mutant MAGEL2 transcripts are detected only in affected
    individuals, confirming the imprinted disease mechanism in these cases.
  mechanism_confidence: ESTABLISHED
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:26365340
    reference_title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Arthrogryposis multiplex congenita (AMC) is characterized by the presence
      of multiple joint contractures resulting from reduced or absent fetal
      movement.
    explanation: >-
      Defines the reduced-fetal-movement mechanism that produces the contracture
      phenotype seen with MAGEL2 truncation.
  - reference: PMID:26365340
    reference_title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In both families, RNA analysis identified the mutated paternal MAGEL2
      transcripts only in affected individuals.
    explanation: >-
      Confirms the paternal-allele, imprinted mechanism in the arthrogryposis
      cases.
  downstream:
  - target: Distal Joint Contractures
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        It usually manifests at birth with muscular hypotonia in all and distal
        joint contractures in a majority of affected individuals.
      explanation: >-
        Reduced fetal movement produces the distal joint contractures seen in a
        majority of individuals.
  - target: Fetal Akinesia and Arthrogryposis Multiplex Congenita
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26365340
      reference_title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Arthrogryposis multiplex congenita (AMC) is characterized by the
        presence of multiple joint contractures resulting from reduced or absent
        fetal movement.
      explanation: >-
        Complete loss of fetal movement manifests as arthrogryposis multiplex
        congenita / fetal akinesia.

phenotypes:
- category: Neurologic
  name: Neonatal Hypotonia
  description: >-
    Muscular hypotonia manifesting at birth is present in essentially all
    affected individuals and is typically the presenting feature.
  phenotype_term:
    preferred_term: Neonatal hypotonia
    term:
      id: HP:0001319
      label: Neonatal hypotonia
    onset:
      onset_category: CONGENITAL
  frequency: OBLIGATE
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It usually manifests at birth with muscular hypotonia in all and distal
      joint contractures in a majority of affected individuals.
    explanation: >-
      GeneReviews states muscular hypotonia is present at birth in all affected
      individuals.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Developmental delay, intellectual disability, and hypotonia represent the
      most common phenotypes, present among all individuals for whom this
      information has been available
    explanation: >-
      The 18-individual cohort corroborates hypotonia as present in all assessed
      individuals.
- category: Musculoskeletal
  name: Distal Joint Contractures
  description: >-
    Distal joint contractures (including camptodactyly / contractures of the
    small finger joints) are present in a majority of affected individuals and
    are a distinguishing feature from Prader-Willi syndrome.
  phenotype_term:
    preferred_term: Distal arthrogryposis
    term:
      id: HP:0005684
      label: Distal arthrogryposis
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It usually manifests at birth with muscular hypotonia in all and distal
      joint contractures in a majority of affected individuals.
    explanation: >-
      GeneReviews states distal joint contractures occur in a majority of
      affected individuals.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia
      to neurobehavioral disease and contractures of the small finger joints.
    explanation: >-
      Fountain et al. document small-finger-joint contractures as part of the
      spectrum.
- category: Neurologic
  name: Developmental Delay and Intellectual Disability
  description: >-
    All affected individuals show developmental delay resulting in intellectual
    disability of variable degree, from low-normal intelligence to severe
    intellectual disability.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: OBLIGATE
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All affected individuals show developmental delay, resulting in
      intellectual disability of variable degree, from low-normal intelligence
      to severe intellectual disability.
    explanation: >-
      GeneReviews states all affected individuals have developmental delay and
      intellectual disability.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Developmental delay, intellectual disability, and hypotonia represent the
      most common phenotypes, present among all individuals for whom this
      information has been available
    explanation: >-
      The 18-individual cohort corroborates DD/ID as present in all assessed
      individuals.
- category: Psychiatric
  name: Autism Spectrum Disorder
  description: >-
    Autism spectrum disorder is characteristic of SYS and is relatively more
    common and severe than in Prader-Willi syndrome; all four individuals in the
    original report met ASD criteria.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  frequency: FREQUENT
  evidence:
  - reference: PMID:24076603
    reference_title: "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All four subjects had autism spectrum disorder (ASD), intellectual
      disability and a varying degree of clinical and behavioral features of
      PWS.
    explanation: >-
      The discovery cohort documents ASD in all affected individuals.
  - reference: PMID:38950199
    reference_title: "MAGEL2 (patho-)physiology and Schaaf-Yang syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Schaaf-Yang syndrome (SYS) is a complex neurodevelopmental disorder
      characterized by autism spectrum disorder, joint contractures, and
      profound hypothalamic dysfunction.
    explanation: >-
      A review lists ASD as a defining feature of SYS.
- category: Gastrointestinal
  name: Feeding Difficulties in Infancy
  description: >-
    Gastrointestinal and feeding problems, including poor suck, are particularly
    pronounced in infancy and childhood and frequently require feeding therapy or
    supplemental tube feeding.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gastrointestinal/feeding problems are particularly pronounced in infancy
      and childhood, but can transition to hyperphagia and obesity in adulthood.
    explanation: >-
      GeneReviews describes prominent infantile feeding problems.
- category: Respiratory
  name: Neonatal Respiratory Distress
  description: >-
    Respiratory distress is present in many individuals at birth, with
    approximately half requiring intubation and mechanical ventilation and about
    20% requiring tracheostomy.
  phenotype_term:
    preferred_term: Neonatal respiratory distress
    term:
      id: HP:0002643
      label: Neonatal respiratory distress
    onset:
      onset_category: CONGENITAL
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Respiratory distress is present in many individuals at birth, with
      approximately half requiring intubation and mechanical ventilation, and
      approximately 20% requiring tracheostomy.
    explanation: >-
      GeneReviews quantifies the frequency and severity of neonatal respiratory
      distress.
- category: Endocrine
  name: Excessive Weight Gain and Obesity
  description: >-
    Early feeding difficulties can transition to excessive weight gain and
    obesity later in childhood or adulthood; obesity and its complications are
    an important contributor to mortality and warrant strict weight monitoring.
    Note that frank PWS-like hyperphagia is uncommon in SYS - most individuals
    do not progress to the hyperphagic nutritional phase - so the frequency
    band below applies to the annotated excessive-weight-gain/obesity term
    rather than to hyperphagia.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  frequency: FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      only eight of 17 molecularly confirmed individuals had excessive weight
      gain, typically associated with PWS
    explanation: >-
      Derived count: 8/17 molecularly confirmed individuals (47%) had excessive
      weight gain, which falls in the HPO FREQUENT band (30-79%). The same
      sentence's surrounding text notes most individuals do not reach the
      hyperphagic phase, which is why the phenotype is scoped to weight
      gain/obesity.
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      but can transition to hyperphagia and obesity in adulthood
    explanation: >-
      GeneReviews notes the transition to hyperphagia and obesity in a subset.
  - reference: PMID:30238631
    reference_title: "The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our clinical report indicates that obesity and its complications are an
      important additional factor in the mortality associated with SYS.
    explanation: >-
      A clinical report links obesity to SYS mortality.
- category: Ophthalmologic
  name: Eye Abnormalities
  description: >-
    Ocular findings are common in SYS and take the form of strabismus,
    esotropia, or myopia.
  phenotype_term:
    preferred_term: Eye abnormality
    term:
      id: HP:0000478
      label: Abnormality of the eye
  frequency: FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eleven of 14 patients manifested eye abnormalities in the form of
      strabismus, esotropia, or myopia.
    explanation: >-
      Derived count: 11/14 patients (79%) had eye abnormalities in the largest
      phenotyping series, placing this in the HPO FREQUENT band (30-79%). The
      generic HP:0000478 term is used because the source bundles strabismus,
      esotropia, and myopia without per-finding counts.
- category: Musculoskeletal
  name: Scoliosis
  description: >-
    Scoliosis is a frequently observed skeletal manifestation.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skeletal manifestations such as joint contractures, scoliosis, and
      decreased bone mineral density are frequently observed.
    explanation: >-
      GeneReviews lists scoliosis among frequently observed skeletal
      manifestations.
- category: Musculoskeletal
  name: Decreased Bone Mineral Density
  description: >-
    Decreased bone mineral density is frequently observed, prompting DXA
    surveillance beginning in childhood.
  phenotype_term:
    preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skeletal manifestations such as joint contractures, scoliosis, and
      decreased bone mineral density are frequently observed.
    explanation: >-
      GeneReviews lists decreased bone mineral density among frequently observed
      skeletal manifestations.
- category: Endocrine
  name: Hypogonadotropic hypogonadism
  description: >-
    Central (hypogonadotropic) hypogonadism has been documented in Schaaf-Yang
    syndrome, consistent with the hypothalamic endocrine involvement shared with
    Prader-Willi syndrome. The evidence is thin: it rests on a single reported
    female with absent spontaneous secondary sexual development, and the same
    cohort states that no systematic endocrinological assessment of the
    syndrome has been published. The broader, better-supported Hypogonadism
    annotation below (cryptorchidism and micropenis in males) is retained
    separately because those male findings are not themselves evidence that the
    defect is gonadotropin-dependent.
  phenotype_term:
    preferred_term: Hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, Patient 18 (Table S3) is a 20-year-old female diagnosed with
      hypogonadotropic hypogonadism."
    explanation: >-
      Direct report of hypogonadotropic (central) hypogonadism in a molecularly
      confirmed Schaaf-Yang individual.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She was diagnosed with hypogonadotropic hypogonadism and presented dysmorphic
      labial development, identifiable upon pubertal maturation."
    explanation: >-
      Recorded as PARTIAL because the same passage states she is the only female
      reported with hypogonadism to date and that no systematic endocrinological
      assessment of the syndrome has been reported, so the frequency and
      consistency of the hypogonadotropic mechanism are not established. No
      frequency band is asserted for this reason.
- category: Endocrine
  name: Hypogonadism
  description: >-
    Hypogonadism, including undescended testes in males, is part of the
    endocrine spectrum shared with Prader-Willi syndrome.
  phenotype_term:
    preferred_term: Hypogonadism
    term:
      id: HP:0000135
      label: Hypogonadism
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other findings may include short stature, seizures, eye anomalies, and
      hypogonadism.
    explanation: >-
      GeneReviews lists hypogonadism among additional findings.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypogonadism in the form of cryptorchidism and/or micropenis was present
      in 8 of 11 male cases and represents one of the earliest recognized
      physical features right after birth.
    explanation: >-
      Sources the FREQUENT band by derived count: 8/11 male cases (73%) in this
      cohort, which falls in the 30-79% band. Note the denominator is male
      cases only; female hypogonadism is separately reported in this cohort as
      recognized in just one individual, so the cohort-wide rate is not
      established.
- category: Growth
  name: Short Stature
  description: >-
    Short stature occurs in a proportion of individuals, and growth hormone
    therapy is used in those with short stature or linear-growth concerns.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: FREQUENT
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other findings may include short stature, seizures, eye anomalies, and
      hypogonadism.
    explanation: >-
      GeneReviews lists short stature among additional findings.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A further assessment of skeletal features showed 12 of 14 cases to have
      small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small
      stature.
    explanation: >-
      Sources the FREQUENT band by derived count: 10/16 cases (63%) had small
      stature, which falls in the 30-79% band.
- category: Neurologic
  name: Seizures
  description: >-
    Seizures occur in a proportion of affected individuals.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other findings may include short stature, seizures, eye anomalies, and
      hypogonadism.
    explanation: >-
      GeneReviews lists seizures among additional findings.
- category: Musculoskeletal
  name: Fetal Akinesia and Arthrogryposis Multiplex Congenita
  description: >-
    At the severe end of the spectrum, truncating MAGEL2 variants cause
    arthrogryposis multiplex congenita and fetal akinesia, which can be lethal
    in the perinatal period.
  phenotype_term:
    preferred_term: Fetal akinesia sequence
    term:
      id: HP:0001989
      label: Fetal akinesia sequence
    onset:
      onset_category: ANTENATAL
  evidence:
  - reference: PMID:26365340
    reference_title: "Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we show that paternal MAGEL2 mutations are also responsible for
      lethal AMC, recapitulating the clinical spectrum of PWS
    explanation: >-
      Establishes lethal arthrogryposis / fetal akinesia at the severe end of
      the MAGEL2 spectrum.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia
      to neurobehavioral disease and contractures of the small finger joints.
    explanation: >-
      Places fetal akinesia at the severe end of the SYS spectrum.
- category: Sleep
  name: Sleep Apnea
  description: >-
    Sleep-disordered breathing / sleep apnea occurs and can require CPAP;
    together with hypotonia and obesity it contributes to respiratory morbidity
    and mortality.
  phenotype_term:
    preferred_term: Sleep apnea
    term:
      id: HP:0010535
      label: Sleep apnea
  frequency: FREQUENT
  evidence:
  - reference: PMID:30238631
    reference_title: "The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we present an infant with SYS who sadly died because of the
      combination of hypotonia, sleep apnea, and obesity.
    explanation: >-
      Documents sleep apnea as a contributor to SYS morbidity/mortality.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sleep abnormalities were commonly seen, with 9 of 13 cases diagnosed with
      sleep apnea.
    explanation: >-
      Sources the FREQUENT band by derived count: 9/13 cases (69%) were
      diagnosed with sleep apnea, which falls in the 30-79% band.
- category: Gastrointestinal
  name: Gastroesophageal Reflux
  description: >-
    Gastroesophageal reflux is frequently reported and is attributed in part to
    the muscular dysfunction associated with early hypotonia. It requires
    standard anti-reflux management.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  frequency: FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sleep apnea, gastroesophageal reflux, and decreased fetal movement are
      frequently reported in SHFYNG.
    explanation: >-
      Direct qualitative frequency statement for gastroesophageal reflux in
      SHFYNG. Per the frequency-evidence guidelines, "frequently reported"
      maps to the FREQUENT band.
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      standard therapy for gastroesophageal reflux disease, metabolic syndrome,
      constipation, skeletal abnormalities, low bone mineral density,
      developmental delay/cognitive impairment, seizures, eye anomalies,
      undescended testes, hypogonadism and pubertal abnormalities, and
      hypothyroidism.
    explanation: >-
      GeneReviews names gastroesophageal reflux disease among the manifestations
      requiring standard therapy in Schaaf-Yang syndrome.
- category: Gastrointestinal
  name: Constipation
  description: >-
    Constipation requires standard therapy and is an explicit item on the
    GeneReviews surveillance schedule at each visit.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  notes: >-
    No frequency band asserted: the GeneReviews management and surveillance
    sentences establish that constipation occurs and is monitored, but neither
    reports a rate, and no count is available in the cited cohort.
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      standard therapy for gastroesophageal reflux disease, metabolic syndrome,
      constipation, skeletal abnormalities, low bone mineral density,
      developmental delay/cognitive impairment, seizures, eye anomalies,
      undescended testes, hypogonadism and pubertal abnormalities, and
      hypothyroidism.
    explanation: >-
      GeneReviews names constipation among the manifestations requiring standard
      therapy in Schaaf-Yang syndrome.
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      monitor for signs and symptoms of constipation, sleep apnea, respiratory
      insufficiency, scoliosis, progression of contractures, and puberty
    explanation: >-
      Constipation is an explicit item on the GeneReviews surveillance schedule,
      corroborating it as a recurrent manifestation rather than an incidental
      finding.
- category: Genitourinary
  name: Cryptorchidism
  description: >-
    Undescended testes are among the earliest recognizable physical features in
    affected males, presenting as part of the hypogonadism spectrum and
    requiring standard management.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  frequency: FREQUENT
  notes: >-
    The 8/11 count below is for cryptorchidism and/or micropenis combined, so it
    is an upper bound on cryptorchidism alone; the FREQUENT band is retained
    because the source also identifies it as one of the earliest recognized
    features in males, but a cryptorchidism-specific rate is not established.
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypogonadism in the form of cryptorchidism and/or micropenis was present
      in 8 of 11 male cases and represents one of the earliest recognized
      physical features right after birth.
    explanation: >-
      Establishes cryptorchidism as a common early feature in affected males,
      with 8/11 male cases (73%) showing cryptorchidism and/or micropenis.
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      standard therapy for gastroesophageal reflux disease, metabolic syndrome,
      constipation, skeletal abnormalities, low bone mineral density,
      developmental delay/cognitive impairment, seizures, eye anomalies,
      undescended testes, hypogonadism and pubertal abnormalities, and
      hypothyroidism.
    explanation: >-
      GeneReviews names undescended testes among the manifestations requiring
      standard therapy.
- category: Endocrine
  name: Hypothyroidism
  description: >-
    Hypothyroidism is part of the endocrine spectrum of Schaaf-Yang syndrome and
    requires standard therapy.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  notes: >-
    No frequency band asserted: GeneReviews names hypothyroidism as a managed
    manifestation but reports no rate, and the cited cohort provides no count. A
    systematic endocrinological assessment of SHFYNG has not been reported.
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      standard therapy for gastroesophageal reflux disease, metabolic syndrome,
      constipation, skeletal abnormalities, low bone mineral density,
      developmental delay/cognitive impairment, seizures, eye anomalies,
      undescended testes, hypogonadism and pubertal abnormalities, and
      hypothyroidism.
    explanation: >-
      GeneReviews names hypothyroidism among the manifestations requiring
      standard therapy in Schaaf-Yang syndrome.
- category: Musculoskeletal
  name: Small Hands
  description: >-
    Small hands are a recurrent acral skeletal feature, part of the
    Prader-Willi-like habitus shared with the 15q11.2 imprinted region.
  phenotype_term:
    preferred_term: Small hand
    term:
      id: HP:0200055
      label: Small hand
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A further assessment of skeletal features showed 12 of 14 cases to have
      small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small
      stature.
    explanation: >-
      Sources the VERY_FREQUENT band by derived count: 12/14 cases (86%) had
      small hands, which falls in the 80-99% band.
- category: Musculoskeletal
  name: Small Feet
  description: >-
    Small feet accompany the small hands as part of the acral skeletal
    phenotype.
  phenotype_term:
    preferred_term: Small feet
    term:
      id: HP:0001773
      label: Short foot
  frequency: FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A further assessment of skeletal features showed 12 of 14 cases to have
      small hands, 8 of 15 to have small feet, and 10 of 16 cases to have small
      stature.
    explanation: >-
      Sources the FREQUENT band by derived count: 8/15 cases (53%) had small
      feet, which falls in the 30-79% band. HP:0001773 Short foot is the closest
      available term, so preferred_term retains the source's "small feet"
      wording.
- category: Craniofacial
  name: Facial Dysmorphism
  description: >-
    A variable spectrum of facial dysmorphism is the single most prevalent
    physical finding in the molecularly confirmed cohort, involving the
    philtrum, ear position, nasal structure, frontal bossing and palpebral
    fissure length, with prognathia and a squared-off chin in the majority of
    older children.
  phenotype_term:
    preferred_term: Facial dysmorphism
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of 18 molecularly confirmed postnatal cases, 16 are described to have a
      spectrum of varying facial dysmorphisms including malformations of the
      philtrum, ear position, nasal structure, frontal bossing and palpebral
      fissure length.
    explanation: >-
      Sources the VERY_FREQUENT band by derived count: 16/18 cases (89%) had
      facial dysmorphism, which falls in the 80-99% band. HP:0001999 Abnormal
      facial shape is the generic parent term; the source describes a variable
      combination of features rather than one consistent gestalt, so no more
      specific term is asserted.
- category: Behavioral
  name: Impulsive and Compulsive Behavioral Profile
  description: >-
    Affected individuals show a characteristic behavioral spectrum described as
    impulsive, compulsive, stubborn, and manipulative, overlapping the
    behavioral profile of Prader-Willi syndrome.
  phenotype_term:
    preferred_term: Impulsive, compulsive, stubborn, and manipulative behaviors
    term:
      id: HP:0000708
      label: Atypical behavior
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An analysis of patient behavior identified a spectrum of abnormalities,
      including impulsive, compulsive, stubborn, and manipulative behaviors
      (seen in nine of 11 cases for which this information was available).
    explanation: >-
      Sources the VERY_FREQUENT band by derived count: 9/11 assessed cases (82%)
      showed the behavioral spectrum, which falls in the 80-99% band. The count
      is reported for the spectrum as a whole, so it is modeled as one node
      under the generic HP:0000708 rather than split across HP:0000722
      Compulsive behaviors and HP:0100710 Impulsivity, which would wrongly
      assign the combined 9/11 frequency to each component.
- category: Behavioral
  name: Habitual Skin Picking
  description: >-
    Habitual skin picking or automutilation of varying severity is reported by
    parents in a majority of molecularly diagnosed individuals, another feature
    shared with Prader-Willi syndrome.
  phenotype_term:
    preferred_term: Habitual skin picking / automutilation
    term:
      id: HP:0100716
      label: Self-injurious behavior
  frequency: FREQUENT
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Parents reported habitual skin picking or automutilation of varying
      severity in seven of 12 molecularly diagnosed individuals.
    explanation: >-
      Sources the FREQUENT band by derived count: 7/12 cases (58%) had habitual
      skin picking, which falls in the 30-79% band. The finding is
      parent-reported rather than systematically ascertained.

biochemical:
- name: Secreted Amyloid-beta 1-40 (Abeta1-40)
  biomarker_term:
    preferred_term: Amyloid beta 1-40
    term:
      id: NCIT:C103353
      label: Amyloid Beta 1-40 Measurement
  presence: decreased
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  notes: >-
    Secreted Abeta1-40 is significantly decreased in cultured fibroblasts from
    individuals with Schaaf-Yang syndrome relative to wild-type controls, and is
    proposed as a candidate biomarker. This is a patient-fibroblast finding (n=7
    patients vs n=11 controls), not a validated clinical assay; the source
    frames it as promising rather than established, and no reference interval
    has been published, so no reference_ranges are curated.
  evidence:
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional studies show significantly decreased levels of secreted
      Aβ1-40 and intracellular glutamine in SYS fibroblasts compared with WT.
    explanation: >-
      Establishes reduced secreted Abeta1-40 in patient fibroblasts versus
      wild-type controls.
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Aβ1-40 secretion levels and HOTAIR mRNA levels might be promising
      biomarkers for SYS.
    explanation: >-
      The authors propose Abeta1-40 secretion as a candidate biomarker, stated
      as a possibility rather than a validated one.
- name: Intracellular Glutamine
  biomarker_term:
    preferred_term: glutamine
    term:
      id: NCIT:C522
      label: Glutamine
  presence: decreased
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  notes: >-
    Targeted metabolomic profiling of patient fibroblasts shows significantly
    decreased intracellular glutamine relative to wild-type controls, in the
    same experiment as the Abeta1-40 finding. Unlike Abeta1-40 and HOTAIR,
    glutamine is not proposed by the authors as a candidate biomarker, so it is
    curated as a measured biochemical abnormality only.
  evidence:
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional studies show significantly decreased levels of secreted
      Aβ1-40 and intracellular glutamine in SYS fibroblasts compared with WT.
    explanation: >-
      Establishes reduced intracellular glutamine in patient fibroblasts versus
      wild-type controls.
- name: HOTAIR Long Non-Coding RNA
  biomarker_term:
    preferred_term: HOTAIR long non-coding RNA
    term:
      id: NCIT:C116287
      label: HOX Transcript Antisense RNA
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  notes: >-
    HOTAIR is among 132 differentially expressed genes identified by
    transcriptomic profiling of patient fibroblasts, and its mRNA level is
    proposed alongside Abeta1-40 as a candidate biomarker. No presence value is
    asserted because the cached text does not state the direction of change.
  evidence:
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We also identified 132 differentially expressed genes, including
      non-coding RNAs (ncRNAs) such as HOTAIR, and many of them related to
      developmental processes and mitotic mechanisms.
    explanation: >-
      Identifies HOTAIR as differentially expressed in patient fibroblasts.
  - reference: PMID:36243518
    reference_title: "Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Aβ1-40 secretion levels and HOTAIR mRNA levels might be promising
      biomarkers for SYS.
    explanation: >-
      The authors propose HOTAIR mRNA level as a candidate biomarker, stated as
      a possibility rather than a validated one.

diagnosis:
- name: Molecular Genetic Testing of MAGEL2
  description: >-
    The diagnosis is established by identifying a heterozygous pathogenic
    variant on the paternally derived MAGEL2 allele. Because MAGEL2 is
    maternally imprinted, determining the parental origin of the variant is
    required to interpret the result, and parental testing is important for
    counseling.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of Schaaf-Yang syndrome is established in a proband by
      identification of a heterozygous pathogenic variant in the paternally
      derived MAGEL2 allele by molecular genetic testing.
    explanation: >-
      GeneReviews states the molecular diagnostic criterion for Schaaf-Yang
      syndrome.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The familial association highlights the importance of parental testing,
      determination of the allelic location of the mutation, and the challenges
      for genetic counseling.
    explanation: >-
      Supports parental testing and allelic-origin determination as part of the
      diagnostic workup, which follows from the imprinted inheritance.
- name: MAGEL2 Testing After Negative Prader-Willi Methylation Analysis
  description: >-
    Schaaf-Yang syndrome is a principal differential diagnosis of Prader-Willi
    syndrome. MAGEL2 testing should be considered in a PWS-like phenotype with
    negative PWS methylation analysis. Neonatal contractures favor Schaaf-Yang
    syndrome, whereas childhood-onset hyperphagia is more characteristic of
    Prader-Willi syndrome, though no single feature is exclusive to either.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given the phenotypic overlap between PWS and SHFYNG, testing for mutations
      in MAGEL2 should be considered in the context of PWS-like phenotypes, but
      negative PWS methylation analysis.
    explanation: >-
      States the diagnostic trigger for MAGEL2 testing: a PWS-like phenotype
      with negative PWS methylation analysis.
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While SHFYNG and PWS share an appreciable amount of common features, and
      no specific feature appears to be exclusive of one or the other condition,
      the presence of contractures at birth makes SHFYNG more likely, while the
      development of hyperphagia in childhood appears to be more characteristic
      of PWS.
    explanation: >-
      Provides the discriminating clinical features between Schaaf-Yang and
      Prader-Willi syndrome, while noting that no feature is exclusive.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    SYS is exceptionally rare and literature-defined; population prevalence and
    incidence remain undetermined.
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Schaaf-Yang syndrome (SYS) is a rare neurodevelopmental disorder that
      shares multiple clinical features with the genetically related
      Prader-Willi syndrome.
    explanation: >-
      GeneReviews classifies SYS as a rare disorder; population prevalence and
      incidence are not established, consistent with an ultra-rare,
      literature-defined disorder.

genetic:
- name: MAGEL2
  gene_term:
    preferred_term: MAGEL2
    term:
      id: hgnc:6814
      label: MAGEL2
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    description: >-
      Autosomal dominant with genomic imprinting; only paternal-allele
      truncating variants are pathogenic.
    evidence:
    - reference: PMID:33570896
      reference_title: "Schaaf-Yang Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The 15q11.2 locus that includes MAGEL2 is maternally imprinted, meaning
        that only the paternally derived allele is expressed while the maternally
        derived allele is inactivated.
      explanation: >-
        GeneReviews establishes the imprinted, paternal-allele-only expression
        underlying MAGEL2's autosomal dominant, maternally imprinted inheritance.
  notes: >-
    SYS is caused by truncating (nonsense/frameshift) variants in the single-exon
    gene MAGEL2 on the paternally expressed allele. Nucleotides c.1990-1996 are a
    recurrent mutational hotspot, with a recurrent c.1996dupC (p.Q666fs)
    variant identified in multiple unrelated individuals.
  evidence:
  - reference: PMID:27195816
    reference_title: "The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases harbor truncating mutations of MAGEL2, and nucleotides
      c.1990-1996 arise as a mutational hotspot, with 10 individuals and 1 fetus
      harboring a c.1996dupC (p.Q666fs) mutation
    explanation: >-
      Documents the truncating-variant class and the c.1996 mutational hotspot.

treatments:
- name: Feeding Therapy and Supplemental Tube Feeding
  description: >-
    Feeding therapy or supplemental (naso-gastric or gastrostomy) tube feeding is
    used for persistent infantile feeding difficulties and failure to thrive.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: gastrostomy
    term:
      id: NCIT:C52006
      label: Gastrostomy
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  target_mechanisms:
  - target: Neonatal Suckling and Feeding Failure
    treatment_effect: BYPASSES
    description: >-
      Tube feeding does not correct the suckling deficit; it delivers nutrition
      through an alternative route, working around the disrupted mechanism.
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Feeding therapy or supplemental tube feeding may be required for
      persistent feeding issues
    explanation: >-
      GeneReviews management recommends feeding therapy / tube feeding.
- name: Oxytocin (Experimental)
  description: >-
    Early postnatal oxytocin administration is an experimental, preclinical
    strategy aimed at the hypothalamic oxytocin deficiency itself rather than at
    compensating for its consequences. In Magel2-deficient mice a single
    injection 3-5 hours after birth rescued the otherwise lethal suckling
    failure. This is NOT established human therapy for Schaaf-Yang syndrome: the
    supporting evidence is model-organism only, the authors' clinical proposal is
    framed for Prader-Willi neonates, and GeneReviews management does not include
    it.
  context: >-
    Experimental / preclinical. Recorded to capture the mechanism-directed
    therapeutic hypothesis and its evidence level, not as a clinical
    recommendation.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: oxytocin
      term:
        id: CHEBI:7872
        label: oxytocin
  target_mechanisms:
  - target: Hypothalamic Oxytocin Deficiency
    treatment_effect: RESTORES
    description: >-
      Exogenous oxytocin replaces the deficient hypothalamic oxytocin signal,
      restoring the suckling behaviour lost in Magel2-deficient neonates.
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20876615
    reference_title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      a single injection of OT, 3-5 h after birth, rescued the phenotype of
      Magel2 mutant pups, allowing all of them to survive
    explanation: >-
      Preclinical proof of concept for oxytocin as a mechanism-directed therapy:
      a single postnatal injection rescued the lethal phenotype in the mouse
      model. Model-organism evidence only, which is why this treatment is
      labelled experimental and carries no human efficacy claim.
  - reference: PMID:20876615
    reference_title: "A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We propose that OT supply might constitute a promising avenue for the
      treatment of feeding difficulties in PW neonates
    explanation: >-
      The authors' own therapeutic proposal, graded PARTIAL because it is
      explicitly a proposal ("might constitute a promising avenue") and is
      framed for Prader-Willi neonates rather than Schaaf-Yang syndrome. The
      read-across rests on shared MAGEL2 involvement, so it supports the
      hypothesis but not clinical use in SYS.
- name: Assisted Ventilation and CPAP
  description: >-
    Assisted ventilation (noninvasive or invasive) is used for neonatal
    respiratory distress, and CPAP is used for sleep apnea.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: artificial respiration
    term:
      id: NCIT:C70909
      label: Mechanical Ventilation
  target_phenotypes:
  - preferred_term: Neonatal respiratory distress
    term:
      id: HP:0002643
      label: Neonatal respiratory distress
  - preferred_term: Sleep apnea
    term:
      id: HP:0010535
      label: Sleep apnea
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      assisted ventilation to include either noninvasive or invasive
      intervention; CPAP for sleep apnea
    explanation: >-
      GeneReviews management recommends assisted ventilation and CPAP.
- name: Growth Hormone Therapy
  description: >-
    Growth hormone therapy is used in individuals with short stature and/or
    linear-growth concerns; polysomnography is recommended for those on
    long-term GH therapy.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: human growth hormone replacement therapy
    term:
      id: NCIT:C15599
      label: Hormone Replacement Therapy
  target_phenotypes:
  - preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      growth hormone therapy in those with short stature and/or linear growth
      concerns
    explanation: >-
      GeneReviews management recommends GH therapy for short stature.
- name: Physical Therapy for Contractures
  description: >-
    Physical therapy and orthopedic management address joint contractures,
    progression of contractures, and scoliosis.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_phenotypes:
  - preferred_term: Distal arthrogryposis
    term:
      id: HP:0005684
      label: Distal arthrogryposis
  evidence:
  - reference: PMID:33570896
    reference_title: "Schaaf-Yang Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      monitor for signs and symptoms of constipation, sleep apnea, respiratory
      insufficiency, scoliosis, progression of contractures, and puberty
    explanation: >-
      GeneReviews surveillance targets contractures and scoliosis, managed with
      physical/orthopedic therapy.
📚

References & Deep Research

References

11
PMID:33570896
Schaaf-Yang Syndrome.
No top-level findings curated for this source.
PMID:24076603
Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism.
No top-level findings curated for this source.
PMID:26365340
Truncating Mutations of MAGEL2, a Gene within the Prader-Willi Locus, Are Responsible for Severe Arthrogryposis.
No top-level findings curated for this source.
PMID:27195816
The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families.
No top-level findings curated for this source.
PMID:30238631
The role of obesity in the fatal outcome of Schaaf-Yang syndrome: Early onset morbid obesity in a patient with a MAGEL2 mutation.
No top-level findings curated for this source.
PMID:23452853
Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination.
No top-level findings curated for this source.
PMID:20876615
A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene.
No top-level findings curated for this source.
PMID:25926624
Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome.
No top-level findings curated for this source.
PMID:36243518
Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2.
No top-level findings curated for this source.
PMID:38950199
MAGEL2 (patho-)physiology and Schaaf-Yang syndrome.
No top-level findings curated for this source.
PMID:38396741
The Pivotal Role of Oxytocin's Mechanism of Thermoregulation in Prader-Willi Syndrome, Schaaf-Yang Syndrome, and Autism Spectrum Disorder.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Schaaf–Yang Syndrome: Comprehensive Disease-Characteristics Report
Edison Scientific Literature 12 citations 2026-07-29T22:40:22.553581

Schaaf–Yang Syndrome: Comprehensive Disease-Characteristics Report

Scope and evidence note. This report prioritizes peer-reviewed human evidence through 2024, especially Castilla‑Vallmanya et al. (published May 2023; DOI 10.1136/jmg-2022-108690), supplemented by recent reviews and animal studies. Because Schaaf–Yang syndrome (SYS) is exceptionally rare, much of the evidence comes from aggregated case series, retrospective cohorts, patient-derived fibroblasts, and model organisms rather than controlled trials. PMID values were not available in the retrieved records; DOI links are therefore supplied rather than risking incorrect PMID assignment.

Executive summary

SYS is a congenital, lifelong Mendelian neurodevelopmental disorder caused principally by a truncating variant affecting the paternally expressed MAGEL2 allele in the imprinted 15q11–q13 Prader–Willi region. Its characteristic combination is neonatal hypotonia and feeding/respiratory difficulty, developmental delay or intellectual disability, autism-related features, sleep and hypothalamic-endocrine abnormalities, and distal joint contractures or arthrogryposis. Although it overlaps Prader–Willi syndrome (PWS), severe intellectual disability, autism, and contractures are more characteristic of SYS, whereas classic PWS hyperphagia and obesity affect only a subset of people with SYS. More than 100 affected individuals had been reported by the 2023 synthesis, but population prevalence and incidence remain unknown. (castillavallmanya2023advancinginschaafyang pages 1-2, camerino2024thepivotalrole pages 3-5)

The leading mechanistic model is: paternal MAGEL2 truncation → impaired endosomal recycling and regulated neuropeptide secretion, plus possible toxic/neomorphic activity of stable nuclear truncated MAGEL2 → disrupted hypothalamic, neuronal, neuromuscular, and endocrine development → multisystem phenotype. No disease-modifying therapy is established; present care is multidisciplinary and symptom directed. Growth hormone replacement is used in selected deficient patients, while oxytocin remains experimental and is supported mainly by early-life animal studies. (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 7-8, schubert2025magel2(patho‐)physiologyand pages 10-11)

The following table provides a compact ontology-ready representation of the evidence.

Domain Evidence-backed finding Suggested ontology/code Evidence type/strength
Disease identifiers Schaaf-Yang syndrome (SYS) is a rare Mendelian neurodevelopmental/imprinting disorder; OMIM 615547; Open Targets disease mapping supports MONDO_0014243; overlaps partly with Prader-Willi syndrome but is clinically distinct (OpenTargets Search: Schaaf-Yang syndrome-MAGEL2, castillavallmanya2023advancinginschaafyang pages 1-2) MONDO: Schaaf-Yang syndrome; OMIM: 615547; category: Mendelian disease; candidate MeSH/Orphanet labels: Schaaf-Yang syndrome Human peer-reviewed review/original synthesis + curated database association; moderate-strong
Synonyms / naming Common names include Schaaf-Yang syndrome and SYS; older literature may describe a Prader-Willi-like syndrome with arthrogryposis due to MAGEL2 (castillavallmanya2023advancinginschaafyang pages 1-2) candidate synonyms: SYS; MAGEL2-related Schaaf-Yang syndrome Human literature synthesis; moderate
Causal gene / imprinting Disease is caused primarily by truncating variants in MAGEL2 on 15q11-q13 affecting the paternally expressed allele; maternal allele is imprinted/silenced, so parental-origin confirmation is clinically important (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1) Gene: MAGEL2; chromosome region: 15q11-q13; inheritance concept: autosomal dominant with genomic imprinting / paternal expression Human molecular genetics; strong
Variant class Reported disease-causing variants are predominantly nonsense or frameshift truncating variants; truncated protein lacks the MAGE homology domain (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1) sequence_variant classes: nonsense_variant; frameshift_variant; truncating variant; loss-of-function with possible neomorphic effect Human molecular genetics + in vitro functional evidence; strong
Pathogenic mechanism summary MAGEL2 normally participates in retrograde transport and endosomal protein recycling; SYS likely reflects both loss of MAGEL2 function and pathogenic effects of a stable truncated protein (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 6-6) GO candidate terms: endosomal transport; retrograde transport, endosome to trans-Golgi network; protein recycling; regulated exocytosis / neuropeptide secretion Human original research + mechanistic interpretation; moderate-strong
Truncated protein behavior In cell studies, truncated MAGEL2 was stable and shifted from mainly cytoplasmic WT localization to predominantly nuclear localization, supporting a possible neomorphic/toxic mechanism beyond simple haploinsufficiency (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 6-6) GO cellular component candidates: nucleus; cytoplasm; endosome; protein localization abnormality In vitro functional study; moderate
Transcriptomic profile Patient fibroblasts showed 132 differentially expressed genes, including ncRNAs; HOTAIR was highlighted as upregulated and proposed as a candidate biomarker (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 7-8) biomarker candidates: HOTAIR mRNA; transcriptomic signature; ncRNA dysregulation Human patient-derived in vitro omics; moderate
Metabolomic / biochemical profile SYS fibroblasts had significantly decreased intracellular glutamine and decreased secretion of amyloid-β1-40 (Aβ1-40); both were proposed as candidate biomarkers, but remain unvalidated clinically (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 6-6) CHEBI candidate: glutamine; biomarker candidates: Aβ1-40 secretion, glutamine level Human patient-derived in vitro metabolomics; moderate
Core phenotype overview Early-onset phenotype commonly includes neonatal hypotonia, developmental delay/intellectual disability, feeding difficulties, endocrine disturbance, sleep problems, autism spectrum features, and joint contractures/arthrogryposis (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 8-9) HPO candidates: Neonatal hypotonia; Global developmental delay; Intellectual disability; Feeding difficulties; Autism; Arthrogryposis multiplex congenita / Camptodactyly; Sleep disturbance Human cohort/literature synthesis; strong
Facial dysmorphism frequency Facial dysmorphism reported in 91.4% (64/70) of cases in compiled cohort data (castillavallmanya2023advancinginschaafyang pages 3-4) HPO candidate: Abnormal facial shape / Facial dysmorphism Human compiled cohort frequency; moderate
Sleep disturbance frequency Sleep disturbance reported in 100% (13/13) of cases with available data in compiled cohort review (castillavallmanya2023advancinginschaafyang pages 3-4) HPO candidate: Sleep disturbance; sleep-disordered breathing candidate Human compiled cohort frequency; moderate, small denominator
Growth hormone deficiency frequency Growth hormone deficiency reported in 72.7% (16/22) of assessed individuals (castillavallmanya2023advancinginschaafyang pages 3-4) HPO candidate: Growth hormone deficiency; endocrine abnormality Human compiled cohort frequency; moderate, small denominator
Camptodactyly / contracture frequency Camptodactyly reported in 50% of compiled cases; contractures/arthrogryposis are a distinguishing SYS feature relative to classic PWS (castillavallmanya2023advancinginschaafyang pages 3-4, castillavallmanya2023advancinginschaafyang pages 1-2) HPO candidates: Camptodactyly; Arthrogryposis multiplex congenita; Joint contracture Human cohort + review; moderate-strong
Hypogonadism frequency Hypogonadism reported in 50% (40/80) of compiled cases (castillavallmanya2023advancinginschaafyang pages 3-4) HPO candidate: Hypogonadism Human compiled cohort frequency; moderate
Other endocrine frequencies Hypothyroidism 29.6%; hypoglycemia 63.6%; temperature instability 62.9%; diabetes insipidus 29.4% in available compiled data (castillavallmanya2023advancinginschaafyang pages 3-4) HPO candidates: Hypothyroidism; Hypoglycemia; Temperature instability; Diabetes insipidus Human compiled cohort frequency; moderate
Hormonal/metabolic phenotype Review evidence notes elevated fasting ghrelin, low IGF-1, increased glucose intolerance/diabetes mellitus prevalence, scoliosis ~33%, abnormal bone mineral density, and that only a minority develop hyperphagia/obesity compared with PWS (camerino2024thepivotalrole pages 3-5, castillavallmanya2023advancinginschaafyang pages 7-8) HPO candidates: Elevated circulating ghrelin; Low IGF-1; Glucose intolerance; Diabetes mellitus; Scoliosis; Decreased bone mineral density; Hyperphagia; Obesity Review synthesizing human studies; moderate
Neurobehavioral phenotype Autism spectrum disorder and more severe intellectual disability are emphasized as relatively more common/severe in SYS than in PWS (castillavallmanya2023advancinginschaafyang pages 1-2, camerino2024thepivotalrole pages 3-5) HPO candidates: Autism; Intellectual disability; Behavioral abnormality Human review/cohort synthesis; moderate-strong
Anatomy: brain / hypothalamus MAGEL2 is expressed predominantly in brain, especially amygdala and hypothalamic nuclei including suprachiasmatic, paraventricular, and supraoptic nuclei; hypothalamic dysfunction is central to pathophysiology (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 7-8) UBERON candidates: brain; hypothalamus; amygdala; paraventricular nucleus of hypothalamus; supraoptic nucleus; suprachiasmatic nucleus Human expression/review evidence; moderate
Anatomy: pituitary developmental relevance Embryonic MAGEL2 transcripts were found in developing hypothalamus/ventral diencephalon and Rathke's pouch, supporting hypothalamo-pituitary developmental involvement and congenital hypopituitarism risk (castillavallmanya2023advancinginschaafyang pages 1-2) UBERON candidates: Rathke pouch; pituitary gland; ventral diencephalon Human embryonic expression study; moderate
Anatomy: muscle / musculoskeletal system Hypotonia, high fat mass with low muscle tone, scoliosis, and joint contractures implicate skeletal muscle and musculoskeletal development/function (camerino2024thepivotalrole pages 3-5, schubert2025magel2(patho‐)physiologyand pages 10-11) UBERON candidates: skeletal muscle tissue; musculoskeletal system; vertebral column; joint Human review + animal references; moderate
Cell types implicated Most plausible disease-relevant cell types are hypothalamic neuroendocrine neurons and broader central neurons; fibroblasts are currently the main patient-derived experimental cell system; muscle cells are implicated by hypotonia phenotype (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1, schubert2025magel2(patho‐)physiologyand pages 10-11) CL candidates: neuron; hypothalamic neuroendocrine cell; fibroblast; skeletal muscle cell Mixed human expression/in vitro/phenotype inference; moderate
Upstream-to-downstream causal chain Paternal MAGEL2 truncation → impaired endosomal recycling / secretory trafficking and altered nuclear localization of truncated protein → hypothalamic neuroendocrine dysfunction and delayed neuronal maturation/synaptic abnormalities → neonatal hypotonia, feeding/respiratory/endocrine abnormalities, developmental delay, autism traits, contractures (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 7-8) GO candidates: neuron development; synapse organization; peptide hormone secretion; endosomal transport; regulated exocytosis Integrative mechanistic model from human and animal evidence; moderate
Synaptic / neuronal maturation evidence Magel2-deficient mice show reduced neurite outgrowth, reduced glutamatergic synapse markers, and delayed neuronal maturation; oxytocin reversed neurite outgrowth abnormalities in culture (schubert2025magel2(patho‐)physiologyand pages 10-11) GO candidates: neurite development; glutamatergic synaptic transmission; synapse maturation Animal + in vitro preclinical evidence; moderate
Diagnostic approach Best current diagnostic route is NGS-based sequencing (single gene, panel, exome, genome) detecting MAGEL2 truncating variants, followed by confirmation of paternal origin because maternal allele is imprinted; phenotype-first clues include neonatal hypotonia, feeding issues, contractures, developmental delay/autism, endocrine/sleep abnormalities (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1) Diagnostic concepts: sequence analysis of MAGEL2; trio exome/genome; parental-origin confirmation; genomic imprinting assessment Human clinical genetics guidance; strong
Differential diagnosis Major differential diagnoses include Prader-Willi syndrome, congenital hypopituitarism syndromes, and historically Opitz-C syndrome / PWS-like disorders with arthrogryposis (castillavallmanya2023advancinginschaafyang pages 8-9, castillavallmanya2023advancinginschaafyang pages 1-2) candidate disease terms: Prader-Willi syndrome; congenital hypopituitarism; Opitz-C syndrome Human literature synthesis; moderate
Real-world management Management is multidisciplinary and symptomatic: neonatal feeding/airway/respiratory support, developmental therapies, autism-informed behavioral care, endocrine evaluation, orthopedic surveillance, and sleep monitoring; recent literature offers practical management guidelines by life stage (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 3-4) MAXO candidates: respiratory support; feeding support; physical therapy; occupational therapy; speech therapy; endocrine system monitoring; orthopedic monitoring; sleep study Human peer-reviewed management synthesis; moderate-strong
Growth hormone treatment Growth hormone deficiency is common and patients may benefit from GH therapy; recent literature references retrospective and multi-year follow-up studies, but robust controlled efficacy/safety data remain limited (castillavallmanya2023advancinginschaafyang pages 3-4, castillavallmanya2023advancinginschaafyang pages 7-8, schubert2025magel2(patho‐)physiologyand pages 14-14) MAXO candidates: growth hormone replacement therapy; endocrine follow-up Human cohort/review evidence; moderate but incomplete
Sleep / respiratory management Sleep disturbance is common and sleep-disordered breathing/polysomnography have been specifically studied in referenced literature; respiratory and sleep surveillance are therefore reasonable parts of care (castillavallmanya2023advancinginschaafyang pages 3-4, schubert2025magel2(patho‐)physiologyand pages 10-11) MAXO candidates: polysomnography; sleep-disordered breathing monitoring; respiratory management Human literature synthesis; moderate
Prognosis / mortality Disease is lifelong; available compiled literature notes 10-13 documented deaths in infancy/childhood, but precise survival estimates and causes-of-death distributions are not yet well established (castillavallmanya2023advancinginschaafyang pages 3-4, castillavallmanya2023advancinginschaafyang pages 8-9) outcome concepts: childhood mortality; chronic neurodevelopmental disability Human compiled literature; weak-moderate due to sparse data
Prevention / counseling No primary prevention exists for de novo disease occurrence; for affected families, genetic counseling should address imprinting, recurrence risk, and reproductive options such as prenatal diagnosis or preimplantation genetic testing when a familial pathogenic variant is known (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1) MAXO candidates: genetic counseling; prenatal molecular diagnosis; preimplantation genetic testing Standard clinical genetics inference anchored to imprinting mechanism; moderate
Animal models Disease-relevant models include Magel2-deficient mice and Magel2 truncation rat models; they recapitulate selected behavioral, neurodevelopmental, thermoregulatory, and muscle-related phenotypes and are used for mechanistic and therapeutic studies (schubert2025magel2(patho‐)physiologyand pages 10-11, schubert2025magel2(patho‐)physiologyand pages 14-14) model organism terms: mouse model; rat model; Magel2-deficient; truncation knock-in candidate Animal/preclinical evidence; moderate
Experimental therapeutics Oxytocin is the best-supported experimental therapeutic concept from preclinical work: early postnatal treatment improved some social/developmental phenotypes in Magel2-deficient models, but optimal window, CNS delivery, and human efficacy remain uncertain (schubert2025magel2(patho‐)physiologyand pages 10-11, schubert2025magel2(patho‐)physiologyand pages 14-14) CHEBI candidate: oxytocin; MAXO candidate: oxytocin therapy Animal/preclinical evidence; moderate, not established clinically
Clinical trials status A search retrieved no clearly relevant SYS-specific interventional clinical trials in the available tool output, underscoring a sparse formal trial landscape (OpenTargets Search: Schaaf-Yang syndrome-MAGEL2) research status concept: no SYS-specific trial captured Trial registry search snapshot; weak-moderate
Explicit knowledge gaps Major gaps include true prevalence/incidence, validated biomarkers, genotype-phenotype correlations by variant, long-term natural history, adult outcomes, standardized QoL metrics, controlled GH and oxytocin studies, and consensus diagnostic/management guidelines across centers (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1, schubert2025magel2(patho‐)physiologyand pages 10-11) research gap annotations: epidemiology unknown; biomarker validation needed; natural history study needed Cross-source synthesis; strong as a gap statement

Table: This table summarizes ontology-ready, evidence-backed facts for Schaaf-Yang syndrome across identifiers, mechanisms, phenotypes, diagnostics, management, and models. It is designed as a compact knowledge-base input with explicit evidence strength and clearly marked gaps.

1. Disease information

Definition and category. SYS is an imprinting-dependent, autosomal Mendelian neurodevelopmental syndrome associated with pathogenic variation in MAGEL2, one of the protein-coding genes in the PWS locus. It is not simply a PWS subtype: the disorders overlap mechanistically and phenotypically but have distinguishable clinical distributions. (castillavallmanya2023advancinginschaafyang pages 1-2)

Identifiers and names. Verified identifiers are OMIM 615547 and MONDO:0014243. Open Targets maps MONDO:0014243 to MAGEL2/ENSG00000254585. MAGEL2 itself is OMIM 605283. Common names are Schaaf–Yang syndrome, SYS, and MAGEL2-related Schaaf–Yang syndrome; older descriptions may use “Prader–Willi-like syndrome due to MAGEL2 mutation.” A dedicated ICD-10, ICD-11, or MeSH code was not established in the retrieved evidence; coding generally requires broader congenital-malformation, neurodevelopmental, or genetic-syndrome categories. (OpenTargets Search: Schaaf-Yang syndrome-MAGEL2, castillavallmanya2023advancinginschaafyang pages 1-2)

The evidence is predominantly aggregated disease-level literature—case series, compiled cohorts, reviews, and experimental studies—not an individual-patient EHR dataset. Individual case observations contribute to these aggregates. (castillavallmanya2023advancinginschaafyang pages 8-9)

2. Etiology, risk, and protective factors

The primary cause is a germline pathogenic variant on the paternal, transcriptionally active MAGEL2 allele. MAGEL2 is maternally imprinted; therefore, an identical variant on the normally silent maternal allele may not cause the classic phenotype. Most well-established SYS variants are nonsense or frameshift changes producing a truncated protein, often lacking the C-terminal MAGE homology domain. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1)

This is not an environmentally acquired, infectious, toxic, or lifestyle-mediated disease. The principal “risk factor” is inheritance or de-novo occurrence of a pathogenic variant on the paternal allele. No validated susceptibility loci, protective alleles, environmental protective factors, or gene–environment interactions are known. Environmental and medical circumstances can nevertheless modify complications—for example, aspiration, undernutrition, untreated sleep-disordered breathing, or endocrine deficiency—but do not cause SYS.

3. Phenotypes

Phenotypes begin predominantly prenatally or neonatally, are highly variable, and generally persist lifelong. Core suggested HPO annotations include neonatal hypotonia, feeding difficulty, global developmental delay, intellectual disability, autism, joint contracture, camptodactyly, arthrogryposis, sleep disturbance, short stature, hypogonadism, and temperature instability. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 3-4)

Reported frequencies from compiled literature must be interpreted using their feature-specific denominators:

  • Facial dysmorphism: 91.4% (64/70).
  • Sleep disturbance: 100% (13/13); the denominator is small and likely clinically selected.
  • Growth-hormone deficiency: 72.7% (16/22).
  • Camptodactyly: approximately 50%.
  • Hypogonadism: 50% (40/80).
  • Hypoglycemia: 63.6%; temperature instability: 62.9%.
  • Hypothyroidism: 29.6%; diabetes insipidus: 29.4%.
  • Scoliosis: approximately 33% in a recent review synthesis. (camerino2024thepivotalrole pages 3-5, castillavallmanya2023advancinginschaafyang pages 3-4)

Neonatal hypotonia, weak suck/feeding difficulty, respiratory compromise, and contractures can be severe. Developmental delay and intellectual disability range from moderate to profound; expressive communication and adaptive independence are often substantially affected. Autism spectrum features and behavioral dysregulation are prominent. Sleep abnormalities, including sleep-disordered breathing, further affect daytime behavior and caregiver burden. (castillavallmanya2023advancinginschaafyang pages 1-2, schubert2025magel2(patho‐)physiologyand pages 10-11)

Endocrine/metabolic findings include short stature, low IGF‑1 or growth-hormone deficiency, hypogonadism, elevated fasting ghrelin, abnormal body composition, glucose intolerance/diabetes, and altered bone mineral density. Unlike classic PWS, only a minority develop marked hyperphagia and obesity, although high fat mass can occur despite a lower BMI. (camerino2024thepivotalrole pages 3-5, castillavallmanya2023advancinginschaafyang pages 7-8)

No robust SYS-specific EQ‑5D, SF‑36, or population-level utility estimates were recovered. Quality-of-life effects are inferred from chronic feeding and sleep problems, communication and intellectual disability, restricted mobility from contractures, behavioral symptoms, and intensive caregiver requirements; caregiver burden has been studied, but quantitative scores were unavailable in the retrieved full text. (schubert2025magel2(patho‐)physiologyand pages 10-11)

4. Genetic and molecular information

Gene: MAGEL2, encoding MAGE family member L2; Open Targets identifier ENSG00000254585. MAGEL2 is a single-exon gene encoding a 1,249-amino-acid protein with an N-terminal proline-rich region and C-terminal MAGE homology domain at approximately residues 1027–1195. (OpenTargets Search: Schaaf-Yang syndrome-MAGEL2, castillavallmanya2023advancinginschaafyang pages 1-2)

Variant interpretation. Established SYS variants are predominantly heterozygous germline nonsense or frameshift variants on the paternal allele. Their population frequency should generally be absent or extremely low in reference databases, but exact gnomAD frequencies must be checked variant by variant. Classification should follow ACMG/AMP criteria while explicitly incorporating phenotype, predicted truncation, functional evidence, segregation, and—critically—parental origin. A VUS or missense variant should not automatically be called SYS without compelling evidence. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1)

The disease mechanism is more complex than ordinary haploinsufficiency. Patient-derived experiments showed that truncated MAGEL2 is synthesized and stable and shifts from predominantly cytoplasmic wild-type localization to predominantly nuclear localization. This supports combined loss of normal endosomal/secretory function and a possible neomorphic or toxic truncated-protein effect. Mild phenotypes reported with complete regional deletions further support the possibility that absence and truncation are not biologically equivalent. (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 6-6)

No validated modifier genes, protective variants, founder variant, anticipation mechanism, or recurrent population-specific allele has been established. Larger 15q abnormalities involving MAGEL2, NDN, MKRN3, or the full PWS region can produce overlapping but non-identical disorders and should not automatically be labeled sequence-variant SYS. (castillavallmanya2023advancinginschaafyang pages 6-6)

5. Environmental information

No toxin, radiation exposure, pollution source, occupation, diet, smoking behavior, alcohol exposure, or infectious agent is known to initiate SYS. There is no zoonotic or transmissible component. Nutrition, airway care, infection prevention, physical activity, and sleep management are clinically important modifiers of morbidity rather than etiologic factors.

6. Mechanism and pathophysiology

MAGEL2 normally contributes to endosomal protein trafficking, retrograde transport, recycling, and neurosecretory function. Loss of normal function can impair the recycling or secretion machinery required by hypothalamic neurons. The downstream result is dysregulated secretion of neuropeptides and pituitary-regulating hormones governing feeding, growth, reproduction, sleep, temperature, stress responses, and social behavior. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 7-8)

Patient-fibroblast evidence provides a second mechanism. In seven SYS fibroblast lines versus 11 controls, investigators found decreased secreted amyloid‑β1–40, decreased intracellular glutamine, and 132 differentially expressed genes, including increased HOTAIR. Truncated MAGEL2 remained stable and accumulated disproportionately in the nucleus. These findings make Aβ1–40 secretion and HOTAIR mRNA candidate biomarkers, but neither is a validated clinical diagnostic test. (castillavallmanya2023advancinginschaafyang pages 1-1)

The authors’ exact abstract conclusion was: “A truncated MAGEL2 protein is stable and localises mainly in the nucleus, where it might exert a pathogenic neomorphic effect.” They further stated that “Aβ1-40 secretion levels and HOTAIR mRNA levels might be promising biomarkers for SYS.” These are hypotheses supported by patient-derived in-vitro data, not yet prospective clinical biomarkers. (castillavallmanya2023advancinginschaafyang pages 1-1)

Animal evidence adds impaired neurite growth, delayed neuronal maturation, and reduced glutamatergic synapse markers. In Magel2-deficient mouse neurons, oxytocin reversed reduced neurite outgrowth, although it did not normalize every glutamatergic synaptic endpoint. Suggested GO annotations include endosomal transport, retrograde endosome-to-trans-Golgi transport, protein recycling, regulated exocytosis, peptide-hormone secretion, neuron development, neurite morphogenesis, synapse organization, and glutamatergic transmission. (schubert2025magel2(patho‐)physiologyand pages 10-11)

There is no established autoimmune, inflammatory, fibrotic, ischemic, or primary mitochondrial mechanism. No reproducible SYS-specific proteomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or integrated multi-omics signature has yet reached clinical validity.

7. Anatomical structures affected

The central nervous system—particularly hypothalamic circuitry—is primary. MAGEL2 expression is enriched in the brain, including the amygdala and hypothalamic suprachiasmatic, paraventricular, and supraoptic nuclei. Suggested UBERON concepts are brain, hypothalamus, amygdala, suprachiasmatic nucleus, paraventricular nucleus, supraoptic nucleus, pituitary gland, skeletal muscle, joint, and vertebral column. (castillavallmanya2023advancinginschaafyang pages 1-2)

Developmental expression in the hypothalamus, ventral diencephalon, and Rathke pouch supports hypothalamo-pituitary involvement. Secondary systems include skeletal muscle and peripheral joints, respiratory/upper-airway structures, gastrointestinal tract, endocrine organs, skeleton, and reproductive system. Candidate CL annotations are neuron, hypothalamic neuroendocrine cell, pituitary endocrine cell, skeletal muscle cell, and fibroblast—the last being an experimental rather than primary disease-target cell. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 1-1)

Relevant subcellular compartments are endosomes, recycling endosomes, cytoplasm, nucleus, and secretory vesicles. No consistent lateralization is recognized.

8. Temporal development

Onset is congenital, often with prenatal reduced movement or contractures and neonatal hypotonia, weak feeding, and respiratory problems. The course is chronic and lifelong rather than relapsing-remitting. Developmental gains occur, but intellectual, communication, orthopedic, sleep, and endocrine needs commonly persist. (castillavallmanya2023advancinginschaafyang pages 1-2)

There is no validated staging system. Practical stages are neonatal stabilization; infancy/early-childhood feeding, motor, and communication intervention; school-age neurobehavioral, orthopedic, sleep, and endocrine surveillance; and adult support for chronic disability and metabolic complications. Early neural development may be a therapeutic critical period: model data suggest that oxytocin effects depend on timing, while CNS delivery becomes more difficult after blood–brain-barrier maturation. This remains a preclinical expert interpretation, not a human treatment window. (schubert2025magel2(patho‐)physiologyand pages 10-11, schubert2025magel2(patho‐)physiologyand pages 14-14)

9. Inheritance and population

Inheritance is best described as autosomal dominant with parent-of-origin-dependent expression. A pathogenic variant causes SYS when present on the active paternal allele. Many cases are de novo; familial transmission is possible, including clinically unaffected maternal carriers whose variant can become disease-causing when transmitted through a male in a later generation. Parental testing and phasing are consequently essential.

Penetrance for established paternal truncating variants appears high, but expressivity is markedly variable. Formal penetrance estimates, carrier frequency, germline-mosaicism rate, founder effects, consanguinity effects, ethnic enrichment, geographic variation, sex ratio, prevalence, and annual incidence are unknown. More than 100 patients had been reported by 2023, which is a literature count rather than an epidemiologic prevalence estimate. (castillavallmanya2023advancinginschaafyang pages 1-2)

10. Diagnostics

Diagnosis requires molecular confirmation; no biochemical, imaging, histologic, or electrophysiologic test is independently diagnostic.

  1. Clinical suspicion: neonatal hypotonia/feeding or respiratory difficulty plus distal contractures or arthrogryposis, developmental delay/intellectual disability, autism features, short stature/endocrine abnormalities, and sleep disturbance.
  2. Sequence testing: trio exome/genome, a neurodevelopmental/arthrogryposis/imprinting-disorder panel containing MAGEL2, or targeted MAGEL2 sequencing.
  3. Parental-origin confirmation: parental sequencing and phasing should determine whether the variant is on the paternal allele.
  4. Structural/imprinting assessment: chromosomal microarray may identify 15q copy-number changes but will miss most small truncating variants. PWS methylation testing is useful when PWS is suspected, but a normal PWS methylation result does not exclude sequence-level SYS. Karyotyping and FISH have low yield unless a large rearrangement is suspected.
  5. Baseline phenotyping: feeding/swallow evaluation; polysomnography when indicated; endocrine tests including glucose, thyroid, IGF‑1/GH-axis and gonadal assessment; orthopedic examination; hearing/vision assessment; and developmental/autism evaluation. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 3-4)

Main differentials include PWS, congenital myopathies, congenital hypopituitarism, L1CAM-related disease when hydrocephalus/spasticity is present, other arthrogryposis syndromes, and historically Opitz-C/PWS-like disorders. PWS is distinguished molecularly by loss of expression across the paternal PWS region and clinically by more typical later hyperphagia/obesity, small hands/feet, and characteristic facies; SYS more strongly features contractures and autism/severe ID. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 8-9)

RNA-seq, metabolomics, Aβ1–40, HOTAIR, and glutamine remain research tools. Newborn or population carrier screening is not standard.

11. Outcome and prognosis

Reliable five- or ten-year survival rates, median life expectancy, and disease-specific mortality rates do not exist. A 2023 compiled analysis identified approximately 10–13 reported deaths in infancy or childhood, but publication bias and incomplete follow-up prevent estimation of risk. Severe neonatal respiratory disease, aspiration/feeding complications, gastrointestinal dysmotility or malrotation, sleep-disordered breathing, endocrine crises, and extreme obesity in occasional patients are plausible contributors. (castillavallmanya2023advancinginschaafyang pages 8-9, castillavallmanya2023advancinginschaafyang pages 3-4)

Long-term morbidity includes intellectual and adaptive disability, limited communication, autism-related behavior, mobility restriction from contractures/scoliosis, sleep problems, endocrine deficiency, altered body composition, and caregiver burden. Full recovery is not expected because the genetic neurodevelopmental disorder is lifelong, although feeding, motor function, communication, sleep, growth, and participation may improve with intervention. No validated prognostic biomarker or risk calculator exists.

12. Treatment and current applications

There is no approved disease-modifying or genotype-corrective treatment. Real-world management is individualized and multidisciplinary:

  • Neonatal respiratory support, aspiration prevention, swallowing assessment, and enteral feeding when necessary.
  • Physical therapy, stretching/splinting, occupational therapy, speech-language and augmentative communication interventions, and developmental/behavioral services.
  • Polysomnography and treatment of obstructive or central sleep-disordered breathing.
  • Endocrinology follow-up for growth, thyroid, glucose, adrenal/pituitary, puberty, gonadal function, and bone health.
  • Orthopedic surveillance for contractures, hip or foot abnormalities, and scoliosis; surgery is phenotype-specific rather than syndrome-specific.
  • Nutritional monitoring without assuming the classic PWS hyperphagia trajectory. (castillavallmanya2023advancinginschaafyang pages 1-2, castillavallmanya2023advancinginschaafyang pages 3-4)

Suggested MAXO terms include genetic counseling, feeding assistance, gastrostomy, respiratory support, polysomnography, physical therapy, occupational therapy, speech therapy, augmentative and alternative communication, growth-hormone replacement, endocrine monitoring, orthopedic surveillance, and scoliosis surgery.

Growth hormone. Growth-hormone deficiency is frequent, and retrospective/multiyear reports suggest improved linear growth and possible body-composition benefits in selected patients. However, SYS-specific controlled response rates and comprehensive long-term safety estimates are unavailable. Treatment should follow endocrine confirmation and include glucose, IGF‑1, scoliosis, and sleep/airway surveillance. (castillavallmanya2023advancinginschaafyang pages 3-4, castillavallmanya2023advancinginschaafyang pages 7-8, schubert2025magel2(patho‐)physiologyand pages 14-14)

Experimental therapy. Oxytocin can improve social or developmental phenotypes and neurite growth in Magel2-deficient models. Yet no human SYS efficacy has been established; developmental timing, dose, route, CNS penetration, and durability remain unresolved. No gene therapy, ASO, RNA therapy, CRISPR treatment, cell therapy, or immunotherapy is clinically available. The registry search retrieved no clearly relevant SYS-specific interventional trial, so no supported NCT identifier can be reported. (schubert2025magel2(patho‐)physiologyand pages 10-11, schubert2025magel2(patho‐)physiologyand pages 14-14)

13. Prevention

There is no lifestyle, vaccine, drug, or environmental intervention that prevents a de-novo MAGEL2 variant. Secondary prevention consists of early molecular diagnosis and prompt feeding, respiratory, developmental, sleep, endocrine, and orthopedic intervention. Tertiary prevention targets aspiration, malnutrition, sleep-related hypoxemia, avoidable contracture, scoliosis progression, diabetes, low bone density, and communication-related behavioral distress.

Genetic counseling should explain parent-of-origin effects, test both parents, consider parental mosaicism where appropriate, and discuss prenatal diagnosis or preimplantation genetic testing when the familial pathogenic variant and informative phase are known. Population newborn screening is not currently justified by an established screening assay or disease-modifying neonatal treatment.

14. Other species and natural disease

No validated naturally occurring veterinary counterpart of human SYS was identified. MAGEL2/Magel2 is evolutionarily conserved among mammals, but there is no evidence of breed-specific disease, zoonotic transmission, or cross-species infection. Mouse and rat phenotypes are engineered research models rather than naturally transmissible disease.

15. Model organisms

Mouse models with paternal Magel2 deficiency reproduce selected neonatal, social, thermoregulatory, neuronal, synaptic, and muscle abnormalities. Primary hippocampal neurons show reduced neurite outgrowth, while developing hippocampus shows delayed maturation and altered glutamatergic synapse markers. Early oxytocin can rescue some—but not all—outcomes. (schubert2025magel2(patho‐)physiologyand pages 10-11)

Rat truncation models more closely represent a truncated-protein genotype and show selected behavioral and physiological abnormalities. Their principal value is testing whether truncation differs from complete gene loss and enabling pharmacologic and longitudinal behavioral studies. (schubert2025magel2(patho‐)physiologyand pages 10-11)

Model limitations are substantial: species-specific imprinting and neurodevelopment, variable allele design, incomplete reproduction of severe human intellectual disability and contractures, and uncertain translation of neonatal oxytocin dosing. Patient-derived fibroblasts provide direct human molecular evidence but do not reproduce hypothalamic neuronal physiology. Patient iPSC-derived hypothalamic neurons or organoids, allele-specific models, and single-cell/spatial studies are important unmet research needs.

Current research priorities and expert assessment

The strongest 2023 advance was recognition that SYS may combine loss of normal MAGEL2 function with active pathology from a stable truncated protein, rather than representing simple MAGEL2 haploinsufficiency. The most important translational priorities are prospective natural-history registries, standardized phenotype and quality-of-life measures, variant- and parent-of-origin-resolved genotype–phenotype studies, validation of Aβ1–40/HOTAIR biomarkers, controlled growth-hormone studies, and carefully designed early-development neuropeptide trials. (castillavallmanya2023advancinginschaafyang pages 1-1, castillavallmanya2023advancinginschaafyang pages 6-6, schubert2025magel2(patho‐)physiologyand pages 14-14)

The evidence base remains constrained by small and overlapping cohorts. Feature percentages should therefore be stored with numerator/denominator and ascertainment metadata, not treated as definitive population frequencies. Likewise, candidate biomarkers and oxytocin should remain annotated as research findings, whereas molecular diagnosis, multidisciplinary surveillance, rehabilitation, respiratory/feeding support, and treatment of documented endocrine deficiencies represent current clinical practice.

References

  1. (castillavallmanya2023advancinginschaafyang pages 1-2): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  2. (camerino2024thepivotalrole pages 3-5): Claudia Camerino. The pivotal role of oxytocin’s mechanism of thermoregulation in prader-willi syndrome, schaaf-yang syndrome, and autism spectrum disorder. International Journal of Molecular Sciences, 25:2066, Feb 2024. URL: https://doi.org/10.3390/ijms25042066, doi:10.3390/ijms25042066. This article has 8 citations.

  3. (castillavallmanya2023advancinginschaafyang pages 1-1): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  4. (castillavallmanya2023advancinginschaafyang pages 7-8): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  5. (schubert2025magel2(patho‐)physiologyand pages 10-11): Tim Schubert and Christian P. Schaaf. Magel2 (patho‐)physiology and schaaf–yang syndrome. Developmental Medicine and Child Neurology, 67:35-48, Jul 2025. URL: https://doi.org/10.1111/dmcn.16018, doi:10.1111/dmcn.16018. This article has 28 citations and is from a highest quality peer-reviewed journal.

  6. (OpenTargets Search: Schaaf-Yang syndrome-MAGEL2): Open Targets Query (Schaaf-Yang syndrome-MAGEL2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  7. (castillavallmanya2023advancinginschaafyang pages 6-6): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  8. (castillavallmanya2023advancinginschaafyang pages 8-9): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  9. (castillavallmanya2023advancinginschaafyang pages 3-4): Laura Castilla-Vallmanya, Mónica Centeno-Pla, Mercedes Serrano, Héctor Franco-Valls, Raúl Martínez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, and Roser Urreizti. Advancing in schaaf-yang syndrome pathophysiology: from bedside to subcellular analyses of truncated magel2. Journal of Medical Genetics, 60:406-415, May 2023. URL: https://doi.org/10.1136/jmg-2022-108690, doi:10.1136/jmg-2022-108690. This article has 15 citations and is from a domain leading peer-reviewed journal.

  10. (schubert2025magel2(patho‐)physiologyand pages 14-14): Tim Schubert and Christian P. Schaaf. Magel2 (patho‐)physiology and schaaf–yang syndrome. Developmental Medicine and Child Neurology, 67:35-48, Jul 2025. URL: https://doi.org/10.1111/dmcn.16018, doi:10.1111/dmcn.16018. This article has 28 citations and is from a highest quality peer-reviewed journal.

Artifacts